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Abstract 
Inflammation and B-cell hyperactivation have been associated with non-Hodgkin 
lymphoma development. This prospective analysis aimed to further elucidate pre-diagnosis 
plasma immune marker profiles associated with non-Hodgkin lymphoma risk. 
We identified 598 incident lymphoma cases and 601 matched controls in Nurses’ Health 
Study and Health Professionals Follow-up Study participants with archived pre-diagnosis plasma 
samples and measured 13 immune marker levels with multiplexed immunoassays. Using 
multivariable logistic regression we calculated odds ratios and 95% confidence intervals per 
standard deviation unit increase in biomarker concentration for risk of non-Hodgkin lymphoma 
and major histologic subtype, stratifying additional models by years (<5, 5 to <10, ≥10) after 
blood draw.  
Soluble interleukin-2 receptor-α, CXC chemokine ligand 13, soluble CD30, and soluble 
tumor necrosis factor receptor-2 were individually positively associated, and B-cell activating 
factor of the tumor necrosis factor family inversely associated, with all non-Hodgkin lymphoma 
and one or more subtypes. The biomarker combinations associated independently with 
lymphoma varied somewhat by subtype and years after blood draw. Of note, the unexpected 
inverse association between B-cell activating factor and chronic lymphocytic leukemia/small 
lymphocytic lymphoma risk (odds ratio: 95% confidence interval: 0.51, 0.43-0.62) persisted 
more than 10 years after blood draw (odds ratio: 0.70; 95% confidence interval: 0.52-0.93). 
In conclusion, immune activation precedes non-Hodgkin lymphoma diagnosis by several 
years. Decreased B-cell activating factor levels may denote nascent chronic lymphocytic 
leukemia many years pre-diagnosis.
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Introduction  
 
Severe immune compromise is a strong risk factor for non-Hodgkin lymphoma (NHL), and B-
cell activation and inflammation have been associated with an increased risk of AIDS-related 
NHL. Elevated pre-diagnosis plasma levels of markers of B-cell stimulation including CXC 
chemokine ligand 13 (CXCL13; a B-cell attracting chemokine),1 interleukin (IL)-6 (a B-cell 
stimulatory cytokine), and soluble (s) CD30 (sCD30; a soluble receptor indicative of B- and T-
cell activation) predicted risk of an AIDS-NHL diagnosis in HIV-positive persons,2-4 in some 
instances as early as five years pre-diagnosis.5 Several of these markers have also demonstrated 
an association with NHL risk in immunocompetent people in prospective studies.6-13 Of interest, 
plasma sCD30 levels were positively associated with NHL risk at 6-10 years9 and even 15-23 
years pre-diagnosis.11 Another small nested case-control study reported a significant 2.5-fold 
increase in NHL risk in women with elevated soluble IL-2 receptor-α levels (sIL-2Rα; a marker 
of T-cell activation and IL-2 upregulation), and marginally significant increases in NHL risk in 
women with higher pre-diagnosis tumor necrosis factor (TNF)-α and soluble TNF-receptor-2 
(sTNF-R2) levels.14 These findings collectively suggest that chronic B-cell stimulation has a role 
in lymphomagenesis in immunocompetent persons.  
Our study aimed to further characterize pre-diagnosis plasma immune marker profiles 
associated with risk of HIV-unrelated NHL and its major histologic subtypes in two large US 
cohorts. This study represents one of the largest populations with prospectively collected pre-
diagnosis blood samples to investigate the association between numerous immune markers and 
NHL risk, including with specific NHL subtypes that are often precluded due to small sample 
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size, and to assess the independence of biomarker-NHL associations for multiple immune 
markers.11, 12 The long-term follow-up of the study population also allowed for examination of 
the influence of time since blood draw on observed immune marker-NHL associations—
including an assessment of potential early markers of lymphomagenesis present ≥10 years prior 
to diagnosis. The choice of immune markers was guided in part by the immune deregulation we 
sought to characterize and by reported findings in AIDS- or HIV-unrelated NHL. We 
hypothesized that pre-diagnosis levels of immune markers indicative of B-cell activation or 
inflammation would be positively associated with risk of developing NHL and major NHL 
subtypes, and that the use of multi-marker models will enhance characterization of the immune 
milieu associated with NHL risk and suggest subtle differences by histologic subtype. 
 
Methods 
Study Population 
The study population comprised Nurses’ Health Study (NHS, all female) and Health 
Professionals Follow-up Study (HPFS, all male) participants with archived plasma 
(Supplementary Methods).15, 16 Cancer diagnoses were identified via routine questionnaires or 
death follow-up17, 18 and confirmed by medical record review or tumor registry linkage.   
Participants provided written informed consent at blood collection. The study was 
conducted in accordance with the Declaration of Helsinki and approved by the Institutional 
Review Boards of the Brigham and Women’s Hospital and Harvard T.H. Chan School of Public 
Health. 
 
Case and Control Selection 
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We included all participants with confirmed incident NHL diagnosed ≥3 months after blood 
draw through December 31, 2010, with no other cancer history. Study pathologists (JCA, SJR) 
classified NHL histologic subtype19 according to World Health Organization20, 21 and 
International Lymphoma Epidemiology (InterLymph) Consortium guidelines.22, 23 We analyzed 
common B-cell (B-) NHL subtypes individually [diffuse large B-cell (DLBCL), follicular (FL) 
and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)], combined less 
common B-NHLs (“other B-NHL”) and defined additional categories by cell type (T-NHL, B-
NHL). We matched one control per case by sex (cohort), age, race and blood draw details 
(Supplementary Methods). 
 
Biomarker Assessment 
Assays were performed at the University of California, Los Angeles (LM, OMM), using 
multiplexed kits (Fluorokine® MAP, R & D Systems, Minneapolis, MN), a Bio-Plex 200 
Luminex instrument and Bio-Plex analysis software (Bio-Rad, Hercules, CA). Blinded 
laboratory personnel measured sCD30, sIL-2Rα, B-cell activating factor of the TNF family 
(BAFF, a B-cell stimulatory cytokine), CXCL13, sIL-6Rα, sGP130, sCD14, sTNF-R2, C-
reactive protein (CRP), IL-6, IL-8, IL-10, and TNF-α concentration according to manufacturer 
directions (Supplementary Methods). We set TNF-α, IL-8 and CXCL13 values to missing for 
samples with >24-hour processing delays (NHS: N= 35; HPFS: N=23). Analyte concentrations 
were natural log-transformed for all analyses. We observed similar measured biomarker 
concentrations for the NHS and HPFS (Supplementary Table 1) and pooled the data. 
 
Statistical Methods 
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We conducted batch calibration to diminish the potential influence of laboratory batch-related 
variability on biomarker-NHL associations.24 Outlying biomarker values were identified using 
the Rosner extreme Studentized deviate method25 and omitted from analyses of the marker.  
The primary analysis assessed batch effect-corrected, log-transformed biomarker values 
continuously per standard deviation (SD) increase in concentration, with SD units calculated for 
log-transformed values in the pooled controls. We calculated odds ratios (OR) and 95% 
confidence intervals (CI) for the association of each biomarker with NHL risk (overall and for 
DLBCL, FL, CLL/SLL, other B-NHL, all B-NHL and all T-NHL) using unconditional logistic 
regression. Models adjusted for all matching factors unless small cell counts precluded 
adjustment for race. We evaluated but did not observe confounding by body mass index and 
autoimmune disease history.  
We intended a priori to identify multi-marker profiles associated with NHL risk via 
mutual adjustment of models for biomarkers that were individually associated. We also 
examined models stratified by follow-up interval (0 to <5, 5 to <10, ≥10 years) and assessed 
heterogeneity by time period using the contrast test.26 The Supplementary Methods describes 
additional analyses designed post hoc. 
 
Results 
In total, 601 cases of NHL (345 NHS and 256 HPFS) were identified and individually matched 
to controls. Three cases were later excluded due to unconfirmed lymphoma status. The final 
analysis thus included 598 cases, including 114 DLBCL, 92 FL, 165 CLL/SLL, 132 other B-
NHL (4 Burkitt lymphoma, 19 lymphoplasmacytic lymphoma, 20 mantle cell lymphoma, 44 
marginal zone lymphoma, 20 other B-NHL, and 25 unclassified B-NHL) and 30 T-NHL, and 
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601 controls. The study population was 96% Caucasian and 58% female. Cases and controls had 
similar covariable distributions, due in part to the matched design (Table 1).  
We omitted 109 individual biomarker measurements (<1% of all measurements) with 
implausible outlying values (NHS: 72; HPFS: 37), the majority (90%) of which were implausibly 
high for the particular marker. Omitted values ranged from one measure of IL-10 to 17 measures 
of IL-8. Spearman correlation coefficients ranged from -0.03 (IL-10 and CXCL13) to 0.58 (sIL-
2Rα and sCD30; Supplementary Table 2). 
Individual immune marker models. Multivariable analyses of individual log-transformed 
immune markers revealed significant associations for all NHL per SD increment of log-
transformed sTNF-R2, sIL-2Rα, CXCL13, sCD30 (all positive) and BAFF (inverse; Table 2). In 
subtype-specific analyses, sTNF-R2 levels were also positively associated with risk of all B-
NHL, FL and CLL/SLL, while CXCL13 was positively associated with risk of all B-NHL, 
DLBCL and FL (Table 2). Levels of sIL-2Rα and sCD30 were positively associated with every 
NHL subtype, including T-NHL. Of interest, the association of BAFF with a 17% decreased risk 
of all NHL appeared to be driven by CLL/SLL, for which risk decreased by 49% per SD increase 
in log-transformed BAFF levels (OR: 0.51; 95% CI: 0.43, 0.62; p<0.001); BAFF was not 
associated with other NHL subtypes in single-marker models. We did not observe significant or 
consistent associations for the remaining immune markers with risk of any NHL endpoint. 
Results from cohort-specific models did not suggest marked differences by sex for these 
associations (Supplementary Table 3).   
 Multi-marker profiles. In the model that mutually adjusted for the five log-transformed 
immune markers that had significant individual associations with NHL endpoints (sTNF-R2, 
sIL-2Rα, CXCL13, sCD30, BAFF), sIL-2Rα, CXCL13 and sCD30 remained significantly 
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associated with a 17-24% increased risk, and BAFF with a 26% decreased risk of all NHL per 
SD increase in log concentration, while sTNF-R2 was no longer significantly associated (Table 
3). Results for all B-NHL risk were similar to those for all NHL, whereas mutual adjustment 
attenuated all the immune marker associations with DLBCL. In the multi-marker model of FL 
risk, sCD30 and BAFF remained independently associated, with a borderline association noted 
for CXCL13 (Table 4). In the multi-marker model of CLL/SLL risk, sIL-2Rα was significantly 
associated with a 50% increase (95% CI: 1.18-1.90), and BAFF with a significant 53% reduction 
(95% CI: 0.38, 0.58), per SD increase in log concentration. Lastly, only sIL-2Rα was 
independently associated with T-NHL risk (OR per SD increase in log concentration: 1.96; 95% 
CI: 1.22, 3.13) in mutually adjusted models.  
The five-marker models using the PLR approach yielded essentially the same effect 
estimates as described above for biomarker associations with the NHL endpoints for the full 
follow-up period (Supplementary Tables 4 and 5). sTNF-R2 had significantly different 
associations with B-NHL and T-NHL (p-value for heterogeneity by subtype=0.04; 
Supplementary Table 4); the associations of CXCL13 and BAFF with individual B-NHL 
subtypes also showed evidence of significant heterogeneity (p-values for heterogeneity by 
subtype=0.007 and <0.0001, respectively; Supplementary Table 5). 
In the covariable-adjusted multi-marker models containing restricted cubic splines, there 
was evidence of non-linearity for two biomarkers, CXCL13 and BAFF, in their associations with 
risk of aggregated endpoints (all NHL, B-NHL and other B-NHL; p-values, tests for significance 
of the curve <0.05), but not for biomarker associations with individual B-NHL subtypes or T-
NHLs. 
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In alternative models using semi-automatic stepwise selection, the final models for all 
NHL and all B-NHL included sIL-2Rα, CXCL13 and sCD30, which were positively associated 
with risk, as well as BAFF, which was inversely associated (Supplementary Table 6). In 
comparison, for DLBCL and FL, the stepwise procedure selected only sCD30 (p=0.004 and 
<0.0001, respectively), and for T-NHL the procedure selected only sIL-2Rα (p=0.002) as 
independently (positively) associated with risk.  Of interest, the stepwise procedure identified 
four immune markers independently associated with risk of CLL/SLL, including BAFF and IL-
10 with significant inverse associations and sIL-2Rα with a significant positive association. The 
stepwise procedure identified three immune markers associated with the combined category of 
other B-NHL subtypes, including significant positive associations for CXCL13 and sIL-2Rα, and 
a significant inverse association for BAFF. 
In the model that included all 13 immune markers, sIL-2Rα, CXCL13, and sCD30 again 
had strong positive associations with risk of all NHL and all B-NHL (Table 5). In the CLL/SLL-
specific model, we observed a significant inverse association with risk for BAFF and also for 
sCD14 and IL-10, and a positive association with sIL2-Rα. BAFF was also significantly 
inversely associated with FL risk, while sCD30 was significantly positively associated with FL 
risk. Only sIL-2Rα was significantly associated with an increased risk of T-NHL. We observed 
suggestive positive associations of DLBCL risk with IL-6, CXCL13 and sCD30 in this 13-
marker model. 
Time-stratified analyses. The analyses stratified by time between blood draw and 
diagnosis/index date suggested that the individual biomarker associations with all NHL 
(Supplementary Table 7) and with NHL subtypes (Supplementary Table 8) varied somewhat 
by length of time after blood draw but did not strongly implicate any additional immune marker-
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NHL associations. The time-stratified five-marker models (Table 3) also suggested variability by 
follow-up interval in the independent associations of those immune markers with future NHL 
risk.  For example, the association of sIL-2Rα with risk of all NHL appeared to be restricted to a 
shorter-term interval, specifically within five years of blood draw (OR: 1.52, 95% CI: 1.09, 2.11; 
Table 3), whereas significant associations of CXCL13 with risk of all NHL were evident only 
five or more years after blood collection (5-<10 years; OR: 1.23, 95% CI: 1.00, 1.52; and >10 
years; OR: 1.21, 95% CI: 1.01, 1.45). sCD30 was most strongly associated with all NHL risk 
within 10 years of blood draw, while BAFF was consistently inversely associated with all NHL 
across time periods. Of note, in subtype-specific time-stratified analyses, sCD30 levels were 
strongly positively associated with risk of FL within five years of blood draw (OR: 4.85, 95% 
CI: 2.02, 11.61), and the association decreased in magnitude with increasing follow-up time. In 
CLL/SLL-specific models, elevated sIL-2Rα was associated with a nearly four-fold increased 
risk within five years of blood draw (OR: 3.71, 95% CI: 1.77, 7.76) but had no clear association 
with longer-term CLL/SLL risk. In contrast, BAFF had significant inverse associations with risk 
of CLL/SLL in all pre-diagnosis time periods, albeit with particularly strong associations with 
risk of CLL/SLL within five or 10 years of blood draw (Table 4).  When modeled using PLR, 
the effect estimates were virtually the same for time period-specific biomarker associations, both 
for the aggregated and the individual NHL endpoints (Supplementary Tables 4 and 5). The 
most prominent differences between the two approaches for assessing heterogeneity by time 
period (PLR with interaction terms vs. time-stratified unconditional logistic regression) pertained 
to the statistical significance of apparent heterogeneity by follow-up period for the associations 
of sTNF-R2 with all B-NHL and FL. For example, for the association of sTNF-R2 with all B-
NHL, the p-value for heterogeneity by follow-up time was 0.04 for the cross-product term in 
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PLR (Supplementary Table 4) and 0.40 for the main model contrast test (Table 3). For the 
association of sTNF-R2 with FL, the p-value for heterogeneity by time period was 0.0007 for the 
cross-product term in PLR (Supplementary Table 5) and 0.11 for the main model contrast test 
(Table 4). Time-stratified results for the multi-marker models identified with stepwise selection 
largely agreed with the main results described above (Supplementary Table 6). 
 
Discussion 
In this pooled analysis within the NHS and HPFS cohorts, we observed significant associations 
between NHL risk and pre-diagnosis levels of specific plasma immune markers, including a 
novel, inverse association between levels of BAFF and risk of CLL/SLL. Positive associations 
between levels of sIL-2Rα, CXCL13, and sCD30 and risk of all NHL and all B-NHL, as well as 
the inverse association of BAFF with risk of all NHL and CLL/SLL, were consistent and 
independent across several analytic approaches to constructing a multi-marker profile associated 
with risk. In contrast, the individual positive associations noted for sTNF-R2 with risk of all 
NHL and some B-NHL endpoints were attenuated upon adjustment for other immune markers, 
suggesting a lack of independence in the association between sTNF-R2 levels and NHL risk. 
Manual selection and automated stepwise-selection of multi-marker profiles yielded fairly 
consistent results for all NHL, but also some differences for individual histologic subtypes, 
particularly for CLL/SLL. We also observed some variation in the associations between NHL 
risk and immune markers by time between blood draw and diagnosis.   
Our findings are in agreement with previous studies reporting associations between 
elevated CXCL13 and/or sCD30 levels and increased NHL risk in HIV-positive and 
immunocompetent populations, including several reports analyzing blood samples taken many 
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years prior to NHL diagnosis.2, 3, 8-13 In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention 
Study, Purdue and colleagues11 prospectively investigated multi-marker models similar to those 
in our analysis and observed independent positive associations for sCD30 with risk of NHL and 
DLBCL when adjusted for other biomarkers. Those observations were detectable more than 15 
years prior to diagnosis. Also similar to our findings, positive associations observed for sTNF-R2 
with NHL did not persist upon adjustment for other immune markers.11 In a prospective analysis 
in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, individual associations of 
CXCL13 and sTNF-R2 with NHL both remained significant with mutual adjustment, with 
correction for multiple comparisons and with restriction to samples collected 8-13 years prior to 
diagnosis.10 
We observed an unexpected yet consistently strong inverse association between BAFF 
levels and CLL/SLL risk. BAFF is a member of the TNF family involved with B cell survival 
and maturation.27 Pre-diagnosis serum BAFF concentrations were positively associated with 
AIDS-NHL, and BAFF overproduction has been associated with systemic autoimmune diseases, 
including systemic lupus erythematosus and Sjögren syndrome,28, 29 which are associated with an 
increased risk of NHL in HIV-negative persons.30, 31 However, systemic autoimmune disorders 
in HIV-negative individuals appear to be preferentially associated with NHL subtypes with a 
different natural history than CLL/SLL.30, 32 Nonetheless, CLL cells are known to express 
multiple BAFF receptors (including TNFRSF13B, TNFRS13C and TNFRSF17),33 and the 
inverse association that we observed is biologically plausible if considered indicative of rapid 
uptake of circulating BAFF by nascent CLL/SLL clones,34 reflecting subclinical progression of 
an indolent tumor whose natural course may extend multiple decades. Consistent with this 
interpretation, several clinical studies have observed lower levels of BAFF in sera from 
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CLL/SLL patients than in healthy controls.35-37 The mechanism for the latter findings is 
unknown; our observation suggests that those underlying physiologic processes may commence 
early in CLL pathogenesis, even 10 or more years pre-diagnosis. Concurrent measurement of 
soluble BAFF receptors and study of cell surface expression of those molecules and 
classification of cases into prognostic subgroups were not feasible for the present study. 
Confirmation of the present findings is warranted in larger populations with specimens suitable 
for determining cell surface marker or gene/protein expression. Additionally, prospective studies 
in patients with monoclonal B-lymphocytosis would be informative to evaluate whether 
circulating BAFF levels can enhance risk stratification for progression to malignancy.38 
We also observed significant associations of elevated sIL-2Rα levels with increased risks 
of all NHL, B-NHL, DLBCL, CLL/SLL and T-NHL, primarily within five years of blood draw. 
One other study reported a positive association between sIL-2Rα levels and NHL risk in an HIV-
negative population with prospective blood collection that persisted after incorporating lag-time 
greater than two years.14 Of note, comparatively high sIL-2Rα levels at diagnosis were also 
associated with poor prognosis in patients with NHL.39-41 Biologically, sIL-2Rα and sCD30 are 
highly correlated (r=0.58 in this study), and both can indicate B and T cell activation;42 in the 
present analysis, both markers remained independently associated with a significant increased 
risk of all NHL and all B-NHL after mutual adjustment. In contrast, only sIL-2Rα was 
significantly associated with an increased risk of T-NHL in the multi-marker models, although 
small sample size (N=30 cases) limited statistical power to detect significant independent 
associations for more strongly correlated biomarkers.  Of interest, we observed the strongest 
positive associations of sIL-2Rα with T-NHL risk within 10 years of blood draw, a novel 
observation that requires confirmation in other populations.  
16 
 
We observed significant positive associations between CXCL13 and risk of all NHL, B-
NHL, and FL, as well as borderline associations with DLBCL and other B-NHL, more than 10 
years after blood draw, suggesting an early role for an immune environment characterized by B-
cell stimulation and aberrant B-cell trafficking. Consistent with this interpretation, a recent, 
large-scale genome-wide association study of FL identified CXCR5, which is the receptor for 
CXCL13, as a potential FL susceptibility locus.43 Further, genetic variation in CXCR5 and 
CXCL13 was associated with serum CXCL13 levels in a study of AIDS-NHL, and elevated 
serum CXCL13 levels were observed in AIDS-NHL cases >3 years prior to diagnosis.2 In 
contrast, elevated sCD30 levels were more strongly associated with increased risk of all NHL, B-
NHL and FL within 10 years of blood draw, with a particularly strong association with FL within 
five years of blood draw. These findings suggest sCD30 may be capturing a more proximal pre-
diagnosis increase in immune activation.  
When assessed with multivariable PLR models rather than the main unconditional 
logistic regression analysis, the associations between immune markers and NHL endpoints did 
not change substantially, whether for aggregated endpoints or the individual B-NHL endpoints. 
The minor discrepancies suggested somewhat improved precision in the PLR models, which 
yielded slightly narrower confidence intervals and slightly stronger p-values for heterogeneity by 
follow-up period for a few of the comparisons. None of the discrepant findings would suggest a 
different interpretation of the time- or subtype-specific model findings, however, and thus we 
retained the unconditional logistic regression models as our primary analysis for methodologic 
consistency across the full series of analyses we conducted. 
In the analyses with restricted cubic splines, we observed evidence of significant non-
linearity for associations of CXCL13 and BAFF with aggregated NHL endpoints. Of note, those 
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endpoints comprise small numbers of diverse histologic subtypes of NHL which may have 
different etiologies. Thus, we believe that the observed non-linear associations more likely 
reflect sampling variability and/or an artifact of potentially heterogeneous subtype-specific 
associations for the subtypes in the endpoint groups than a true biological effect. 
Together, our findings add new insight to previous publications on both AIDS-NHL and 
HIV-unrelated NHL risk, collectively suggesting that higher levels of immune activation, and in 
particular heightened B-cell stimulation, may affect B-cell lymphomagenesis. Interestingly, 
several markers of immune activation appear to be elevated many years prior to NHL diagnosis 
and thus could help identify populations at higher risk for developing NHL. It is important to 
note that some reported associations between immune markers and all NHL risk were not 
replicated in analyses of individual histologic subtypes; this may be due in part to subtype-
specific sample sizes that limited statistical power. Significant associations between immune 
markers and risk of all NHL may reflect commonalities in subtype etiologies; however, these 
findings may also conceal a more specific association with one or more of the less common 
subtypes, as illustrated by the present findings for BAFF and CLL/SLL.  
This analysis of immune markers measured from prospectively collected blood 
specimens from two large US cohorts with lengthy follow-up identified several statistically 
significant associations with the risk of developing NHL, including associations that remained 
statistically significant for blood samples collected five or more years prior to diagnosis. 
Although our main results were fairly consistent across analytical approaches, slight variations in 
markers chosen by a priori and secondary analyses emphasize the importance of utilizing diverse 
panels of immune markers in future studies seeking to characterize conditions conducive to NHL 
development. Furthermore, our findings suggest that even though an activated immune milieu 
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may contribute to the development of multiple types of NHL, there is evidence of subtle 
differences in the pathogenesis of individual NHL subtypes, some of which had not been 
previously reported. Larger pooled studies will be important to more accurately identify 
homogeneous and heterogeneous biomarkers of risk or early disease by NHL subtype and to 
elucidate which are more indicative of earlier or later pathogenic changes to the immune 
environment.  
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Table 1. Characteristics of non-Hodgkin lymphoma cases and matched controls from two 
prospective cohort studies 
Variable Cases Controls P* 
Cohort    
NHS 344 (58%) 345 (57%) 0.97 
HPFS 254 (42%) 256 (43%)  
Age, years, Mean ± SD 60.8 ± 8.1 60.8 ± 8.1 0.87 
Race/ethnicity    
   Caucasian 573 (96%) 578 (96%) 0.75 
   Other 25 (4%) 23 (4%)  
BMI at blood draw, kg/m²    
   Less than 22.5 138 (23%) 118 (20%) 0.58 
   22.5-24.9 139 (23%) 166 (28%)  
   25-29.9 217 (36%) 219 (36%)  
  30 or greater 74 (12%) 74 (12%)  
   Missing 30 (5%) 24 (4%)  
BMI in young adulthood, kg/m²    
   Less than 18.5 44 (7%) 54 (9%) 0.31 
   18.5-22.4 298 (50%) 299 (50%)  
   22.5-24.9 126 (21%) 112 (19%)  
   25 or greater 106 (18%) 101 (17%)  
   Missing 24 (4%) 35 (6%)  
Autoimmune disease†    
    Yes 97 (16%) 104 (17%) 0.62 
    No 501 (84%) 497 (83%)  
Years from blood draw to index date, 
Mean ± SD 9.6 ± 5.6 9.6 ± 5.6 0.99 
Cell type/histologic subtype of NHL‡    
   B-NHL 503 (84%)   
     DLBCL 114 (19%)   
     Follicular lymphoma 92 (15%)   
     CLL/SLL 165 (28%)   
     Other B-cell subtypes§ 132 (22%)   
T-NHL 30 (5%)   
Abbreviations: NHS, Nurses' Health Study; HPFS, Health Professionals Follow-up Study; BMI, 
body mass index; NHL, non-Hodgkin lymphoma; B-NHL, B-cell NHL; DLBCL, diffuse large B-
cell lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; and T-
NHL, T-cell NHL. 
* P-values from a Chi-square test or ANOVA. Tests for BMI at blood draw and BMI in young 
adulthood did not include individuals missing data for those variables. 
† Defined as any self-reported diagnosis of rheumatoid arthritis, ulcerative colitis, multiple 
sclerosis, psoriasis, or Sjögren syndrome. 
‡ Information on cell type was not available for 11% of NHL cases. 
§ The other B-NHL subtypes include Burkitt lymphoma (N=4), lymphoplasmacytic lymphoma 
(N=19), mantle cell lymphoma (N=20), marginal zone lymphoma (N=44), other B-NHL (N=20), 
and unclassified B-NHL (N=25). 
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Table 2. Associations between pre-diagnosis concentrations of 13 individual immune markers and risk of Non-Hodgkin Lymphoma (NHL), overall and by major histologic 
subtype 
                          
  
  All NHL*   B-NHL Subtypes All T-NHL   
  
    DLBCL FL CLL/SLL Other B-NHL†       
Marker 
N cases/ 
controls OR (95% CI)‡ 
N 
cases OR (95% CI)‡ 
N 
cases OR (95% CI)‡ 
N 
cases OR (95% CI)‡ 
N 
cases OR (95% CI)‡ 
N 
cases OR (95% CI)‡ P § 
IL-6 597/600 0.97(0.87,1.08) 114 1.12(0.91,1.37) 92 0.90(0.73,1.12) 165 0.99(0.84,1.17) 131 0.89(0.74,1.08) 30 1.13(0.78,1.63) 0.46 
IL-8 558/566 1.00(0.88,1.13) 106 0.96(0.77,1.22) 84 1.07(0.84,1.36) 156 0.98(0.81,1.20) 120 1.11(0.90,1.37) 29 0.82(0.54,1.26) 0.70 
IL-10 596/597 1.00(0.89,1.11) 113 1.14(0.93,1.40) 91 0.98(0.78,1.22) 165 0.85(0.72,1.01) 132 1.04(0.86,1.25) 30 1.21(0.83,1.76) 0.18 
TNF-α 566/571 1.02(0.91,1.14) 108 0.98(0.80,1.21) 87 1.16(0.92,1.47) 158 1.06(0.89,1.26) 120 0.82(0.68,1.00) 29 1.14(0.78,1.67) 0.17 
CRP 596/599 1.06(0.94,1.19) 114 1.12(0.92,1.38) 92 1.12(0.89,1.40) 165 0.93(0.77,1.12) 130 1.15(0.94,1.40) 30 0.97(0.66,1.42) 0.50 
sCD14 592/596 1.01(0.90,1.15) 114 0.90(0.72,1.13) 90 0.97(0.76,1.25) 164 0.91(0.75,1.11) 130 1.14(0.93,1.40) 30 0.94(0.62,1.43) 0.55 
sGP130 592/596 1.03(0.89,1.18) 114 0.87(0.66,1.15) 91 1.15(0.90,1.47) 163 1.00(0.80,1.25) 130 0.99(0.79,1.26) 30 0.81(0.48,1.36) 0.57 
sTNF-R2 592/601 1.25(1.12,1.40) 114 1.02(0.83,1.26) 90 1.37(1.10,1.70) 164 1.28(1.08,1.51) 129 1.35(1.13,1.62) 30 1.03(0.70,1.50) 0.20 
sIL-6Rα 592/599 1.10(0.98,1.23)   114 0.89(0.72,1.10) 91 1.16(0.93,1.44) 165 1.15(0.97,1.36) 128 1.13(0.93,1.37) 30 1.01(0.69,1.46) 0.32 
BAFF 592/601 0.83(0.75,0.92) 114 0.99(0.81,1.21) 92 0.93(0.73,1.17) 163 0.51(0.43,0.62) 128 0.87(0.73,1.05) 30 1.26(0.87,1.82) <0.0001 
sIL-2Rα 585/600 1.37(1.23,1.53) 114 1.26(1.04,1.54) 91 1.55(1.25,1.94) 162 1.49(1.27,1.76) 126 1.40(1.16,1.68) 30 1.97(1.37,2.85) 0.26 
CXCL13 554/571 1.31(1.17,1.46) 107 1.25(1.03,1.52) 86 1.58(1.28,1.95) 156 1.10(0.93,1.31) 116 1.48(1.24,1.76) 28 1.23(0.86,1.76) 0.06 
sCD30 590/600 1.37(1.23,1.52) 114 1.29(1.06,1.56) 90 1.76(1.44,2.15) 163 1.33(1.13,1.57) 131 1.29(1.09,1.54) 29 1.46(1.05,2.04) 0.15 
Abbreviations: NHL, non-Hodgkin lymphoma; B-NHL, B-cell non-Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic 
leukemia/small lymphocytic lymphoma; T-NHL, all T-cell NHL; OR, Odds Ratio; and CI, Confidence Interval; IL, interleukin; TNF, tumor necrosis factor; CRP, C-reactive protein; sCD14, 
soluble CD14; sGP130, soluble GP130; sTNF-R2, soluble tumor necrosis factor receptor-2; sIL-6Rα, soluble interleukin-6 receptor-α; BAFF, B-cell activating factor of the TNF family; sIL-
2Rα, soluble interleukin-2 receptor-α; CXCL13, CXC chemokine ligand 13; sCD30, soluble CD30. 
* The all B-NHL (N=503 cases) results were similar to the all NHL results.  
† Other B-NHL subtypes included Burkitt lymphoma (N=4), lymphoplasmacytic lymphoma (N=19), mantle cell lymphoma (N=20), marginal zone lymphoma (N=44), other B-NHL (N=20), 
and unclassified B-NHL (N=25).  
‡ Odds ratios and 95% confidence intervals were calculated per 1 standard deviation increase in log biomarker concentration, based on batch-corrected values with outliers removed, for 
NHS and HPFS cohorts combined. All models except those for T-NHL were adjusted for age at blood draw (continuous), cohort, time of blood draw (continuous), race (Caucasian/other); 
the models for T-NHL were adjusted for age and cohort only. 
§ P-values for heterogeneity by subtype from contrast tests comparing immune marker-specific estimates between DLBCL, FL, CLL/SLL, other B-NHL and T-NHL. 
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Table 3. Independent associations of multiple pre-diagnosis plasma immune markers with risk of NHL, overall and by B or T cell type of origin, for the complete 
follow-up period and stratified by years of follow-up 
  
        Years from blood draw to diagnosis/index date 
  
  Complete follow-up period   0 to less than 5   5 to less than 10   10 or more   
Marker N cases/ 
controls 
OR (95% CI)   
per 1-SD *,† 
  
N cases/ 
controls 
OR (95% CI)  per 
1-SD *,† 
  
N cases/ 
controls 
OR (95% CI)  per 
1-SD *,† 
  
N cases/ 
controls 
OR (95% CI)  per 
1-SD *,† 
p-value‡ 
All NHL       
  
    
  
    
  
  
  
sTNF-R2 542/571 1.05 (0.91, 1.21)   133/140 0.83 (0.60, 1.14)   149/162 1.02 (0.77, 1.35)   260/267 1.18 (0.95, 1.46) 0.20 
sIL-2Rα 542/571 1.20 (1.03, 1.39)   133/140 1.52 (1.09, 2.11)   149/162 1.16 (0.88, 1.53)   260/267 1.11 (0.88, 1.39) 0.28 
CXCL13 542/571 1.17 (1.03, 1.32)   133/140 1.00 (0.78, 1.29)   149/162 1.30 (1.03, 1.62)   260/267 1.21 (1.01, 1.46) 0.32 
sCD30 542/571 1.24 (1.06, 1.45)   133/140 1.52 (1.09, 2.13)   149/162 1.43 (1.07, 1.90)   260/267 0.98 (0.78, 1.23) 0.02 
BAFF 542/571 0.74 (0.66, 0.83)   133/140 0.73 (0.59, 0.91)   149/162 0.61 (0.48, 0.78)   260/267 0.83 (0.69, 1.00) 0.15 
    
     
                
All B-NHL       
                  
sTNF-R2 454/570 1.07 (0.92, 1.25)   110/140 0.88 (0.63, 1.23)   118/161 1.15 (0.86, 1.54)   226/267 1.13 (0.90, 1.42) 0.40 
sIL-2Rα 454/570 1.20 (1.03, 1.41)   110/140 1.51 (1.06, 2.14)   118/161 1.12 (0.84, 1.49)   226/267 1.15 (0.91, 1.46) 0.38 
CXCL13 454/570 1.13 (1.00, 1.29)    110/140 0.96 (0.74, 1.25)   118/161 1.17 (0.92, 1.49)   226/267 1.24 (1.02, 1.50) 0.31 
sCD30 454/570 1.24 (1.05, 1.46)   110/140 1.59 (1.10, 2.28)   118/161 1.58 (1.14, 2.20)   226/267 0.96 (0.75, 1.22) 0.02 
BAFF 454/570 0.73 (0.64, 0.83)    110/140 0.67 (0.53, 0.84)   118/161 0.64 (0.50, 0.81)   226/267 0.84 (0.69, 1.02) 0.14 
                        
  
All T-NHL       
                  
sTNF-R2 28/569 0.62 (0.37, 1.03)   11/140 0.44 (0.17, 1.19)   10/160 0.65 (0.27, 1.58)   7/267 0.73 (0.24, 2.21) 0.78 
sIL-2Rα 28/569 1.96 (1.22, 3.13)   11/140 2.10 (0.95, 4.68)   10/160 2.20 (0.93, 5.20)   7/267 1.04 (0.36, 3.00) 0.50 
CXCL13 28/569 1.11 (0.75, 1.65)   11/140 1.03 (0.48, 2.22)   10/160 1.37 (0.78, 2.42)   7/267 0.57 (0.24, 1.37) 0.26 
sCD30 28/569 1.33 (0.84, 2.10)   11/140 1.68 (0.69, 4.08)   10/160 1.34 (0.56, 3.21)   7/267 1.77 (0.70, 4.43) 0.90 
BAFF 28/569 0.88 (0.58, 1.32)   11/140 0.93 (0.52, 1.67)   10/160 0.55 (0.24, 1.28)   7/267 1.68 (0.64, 4.44) 0.23 
Abbreviations: NHL, non-Hodgkin lymphoma; B-NHL, B-cell NHL; T-NHL, T-cell NHL; OR, odds ratio; CI, confidence interval; SD, standard deviation; sTNF-R2, soluble 
tumor necrosis factor receptor-2; sIL-2Rα, soluble interleukin-2 receptor-α; CXCL13, CXC chemokine ligand 13; sCD30, soluble CD30; BAFF, B-cell activating factor of 
the TNF family.  
* Models were adjusted for age at blood draw (continuous), cohort (sex), time of blood draw (continuous) and race/ethnicity (Caucasian, non-Caucasian) and were 
mutually adjusted for all markers listed, except that models for all T-NHL were not adjusted for race.  
†
 Odds ratios and 95% confidence intervals were calculated per 1-standard deviation increase in batch effect-corrected, log-transformed values (with cohort-specific 
outliers excluded) from the Nurses’ Health Study and Health Professionals Follow-up Study combined.  
‡ P-values from tests for heterogeneity comparing immune marker-specific estimates across time strata. 
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Table 4. Independent associations of multiple pre-diagnosis plasma immune markers with risk of NHL by major histologic subtype of B-cell NHL, 
for the complete follow-up period and stratified by years of follow-up 
        Years from blood draw to diagnosis/index date   
  
Complete follow-up period  0 to less than 5  5 to less than 10  10 or more   
Marker N cases/ 
controls 
OR (95% CI)  per 
1-SD*, †   
N cases/ 
controls 
OR (95% CI)  per 
1-SD*, †   
N cases/ 
controls 
OR (95% CI)  per 
1-SD*, †   
N cases/ 
controls 
OR (95% CI)  per 
1-SD*, † 
p-
value‡ 
DLBCL     
                  
sTNF-R2 107/570 0.81 (0.62, 1.07)   25/140 0.61 (0.34, 1.10)   25/161 1.05 (0.60, 1.85)   57/267 0.83 (0.56, 1.24) 0.42 
sIL-2Rα 107/570 1.18 (0.91, 1.53)   25/140 1.83 (1.00, 3.37)   25/161 1.19 (0.67, 2.11)   57/267 1.09 (0.75, 1.58) 0.35 
CXCL13 107/570 1.17 (0.95, 1.45)   25/140 0.71 (0.43, 1.19)   25/161 1.42 (0.95, 2.12)   57/267 1.30 (0.95, 1.79) 0.09 
sCD30 107/570 1.23 (0.95, 1.59)   25/140 0.90 (0.48, 1.67)   25/161 1.76 (1.07, 2.89)   57/267 1.09 (0.75, 1.59) 0.19 
BAFF 107/570 0.95 (0.76, 1.18)   25/140 0.96 (0.59, 1.55)   25/161 0.69 (0.44, 1.08)   57/267 1.08 (0.78, 1.50) 0.27 
FL       
                  
sTNF-R2 83/569 1.03 (0.77, 1.38)   18/140 0.45 (0.16, 1.25)   22/160 0.95 (0.53, 1.69)   43/267 1.35 (0.93, 1.96) 0.11 
sIL-2Rα 83/569 1.06 (0.78, 1.46)   18/140 0.93 (0.35, 2.44)   22/160 1.09 (0.63, 1.89)   43/267 1.09 (0.70, 1.68) 0.95 
CXCL13 83/569 1.24 (0.98, 1.58)   18/140 1.10 (0.58, 2.06)   22/160 1.12 (0.72, 1.75)   43/267 1.48 (1.03, 2.13) 0.56 
sCD30 83/569 1.69 (1.26, 2.26)   18/140 4.85 (2.02, 11.61)   22/160 1.88 (1.04, 3.40)   43/267 1.06 (0.68, 1.64) 0.007 
BAFF 83/569 0.76 (0.59, 0.98)   18/140 0.70 (0.38, 1.30)   22/160 0.72 (0.41, 1.24)   43/267 0.78 (0.55, 1.12) 0.94 
CLL/SLL     
                  
sTNF-R2 153/569 1.21 (0.96, 1.52)   36/140 0.98 (0.49, 1.93)   44/160 1.27 (0.81, 1.98)   73/267 1.16 (0.85, 1.58) 0.82 
sIL-2Rα 153/569 1.50 (1.18, 1.90)   36/140 3.71 (1.77, 7.76)   44/160 1.39 (0.90, 2.15)   73/267 1.26 (0.87, 1.83) 0.04 
CXCL13 153/569 0.90 (0.74, 1.10)   36/140 0.78 (0.48, 1.27)   44/160 0.80 (0.54, 1.20)   73/267 1.04 (0.77, 1.41) 0.48 
sCD30 153/569 1.15 (0.89, 1.48)   36/140 1.43 (0.71, 2.87)   44/160 1.54 (0.96, 2.46)   73/267 0.90 (0.62, 1.30) 0.17 
BAFF 153/569 0.47 (0.38, 0.58)   36/140 0.32 (0.19, 0.53)   44/160 0.39 (0.25, 0.61)   73/267 0.63 (0.46, 0.86) 0.05 
Other B-NHL^ 
      
    
  
    
  
  
  
sTNF-R2 111/569 1.17 (0.92, 1.49)   31/140 1.28 (0.78, 2.12)   27/160 1.17 (0.73, 1.90)   53/267 1.11 (0.77, 1.61) 0.90 
sIL-2Rα 111/569 1.15 (0.89, 1.48)   31/140 1.07 (0.62, 1.83)   27/160 1.05 (0.63, 1.74)   53/267 1.29 (0.87, 1.91) 0.77 
CXCL13 111/569 1.45 (1.19, 1.77)    31/140 1.50 (0.98, 2.30)   27/160 1.52 (1.07, 2.17)   53/267 1.36 (0.98, 1.88) 0.88 
sCD30 111/569 1.08 (0.82, 1.41)   31/140 1.28 (0.73, 2.26)   27/160 1.37 (0.81, 2.32)   53/267 0.79 (0.52, 1.21) 0.20 
BAFF 111/569 0.78 (0.64, 0.95)   31/140 0.74 (0.53, 1.04)  27/160 0.72 (0.48, 1.07)  53/267 0.89 (0.64, 1.24) 0.66 
Abbreviations:  NHL, non-Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; B-
NHL, B-cell NHL; OR, odds ratio; CI, confidence interval; SD, standard deviation; sTNF-R2, soluble tumor necrosis factor receptor-2; sIL-2Rα, soluble interleukin-2 receptor-α; CXCL13, 
CXC chemokine ligand 13; sCD30, soluble CD30; BAFF, B-cell activating factor of the TNF family. 
* All models were adjusted for age at blood draw (continuous), cohort (sex), time of blood draw (continuous) and race/ethnicity (Caucasian, non-Caucasian), and were mutually adjusted 
for all markers listed, except that models for other B-NHL were not adjusted for race. 
† Odds ratios and 95% confidence intervals were calculated per 1-standard deviation increase in batch effect-corrected, log-transformed values (with cohort-specific outliers excluded) 
from the Nurses’ Health Study and Health Professionals Follow-up Study combined. 
‡ P-values from tests for heterogeneity comparing immune marker-specific estimates across time strata. 
§ Other B-NHL subtypes included Burkitt lymphoma (N=4), lymphoplasmacytic lymphoma (N=19), mantle cell lymphoma (N=20), marginal zone lymphoma (N=39), other B-NHL (N=20), 
and unclassified B-NHL (N=25).   
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Table 5. Associations of pre-diagnosis plasma immune markers with risk of NHL, with mutual adjustment for all thirteen immune markers, for all NHL and by major histologic 
subtype 
  
All NHL  B-NHL Subtypes All T-NHL   
  
 DLBCL FL CLL/SLL Other B-NHL‡  
Marker 
N 
Cases/ 
Controls 
OR (95% CI)       
per 1-SD *,† 
N 
cases 
OR (95% CI)       
per 1-SD *,† 
N 
cases 
OR (95% CI)        
per 1-SD *,† 
N 
cases 
OR (95% CI)       
per 1-SD *,† 
N 
cases 
OR (95% CI)        
per 1-SD *,† 
N 
cases 
OR (95% CI)      
per 1-SD *,† 
IL-6 523/550 1.06 (0.93, 1.21) 104 1.22 (0.96, 1.55) 78 0.86 (0.66, 1.12) 150 1.10 (0.89, 1.37) 106 1.03 (0.81, 1.31) 28 1.10 (0.71, 1.73) 
IL-8 523/550 0.96 (0.83, 1.10) 104 0.92 (0.72, 1.18) 78 0.94 (0.71, 1.24) 150 1.00 (0.79, 1.26) 106 1.11 (0.88,1.38) 28 0.65 (0.40, 1.07) 
IL-10 523/550 0.95 (0.84, 1.07) 104 1.14 (0.91, 1.43) 78 0.93 (0.72, 1.22) 150 0.80 (0.65, 0.99) 106 0.99 (0.79, 1.23) 28 1.19 (0.77, 1.82) 
TNF-α 523/550 1.00 (0.87, 1.15) 104 0.84 (0.66, 1.08) 78 1.09 (0.81, 1.46) 150 1.09 (0.87, 1.37) 106 0.86 (0.67, 1.10) 28 1.18 (0.74, 1.89) 
CRP 523/550 1.00 (0.87, 1.15) 104 1.07 (0.84, 1.37) 78 1.29 (0.96, 1.72) 150 0.82 (0.65, 1.04) 106 1.00 (0.77, 1.29) 28 0.85 (0.54, 1.34) 
sCD14 523/550 0.84 (0.71, 1.00) 104 0.82 (0.61, 1.11) 78 0.84 (0.61, 1.18) 150 0.68 (0.51, 0.89) 106 0.92 (0.68, 1.24) 28 0.90 (0.51, 1.56) 
sGP130 523/550 1.06 (0.85, 1.32) 104 1.05 (0.71, 1.55) 78 1.20 (0.78, 1.86) 150 1.11 (0.78, 1.58) 106 0.84 (0.57, 1.22) 28 0.76 (0.36, 1.60) 
sTNF-R2 523/550 1.06 (0.86, 1.31) 104 0.96 (0.67, 1.37) 78 0.88 (0.57, 1.36) 150 1.33 (0.94, 1.87) 106 1.16 (0.81, 1.65) 28 0.75 (0.38, 1.46) 
sIL-6Rα 523/550 1.03 (0.89, 1.20) 104 0.86 (0.66, 1.12) 78 1.02 (0.74, 1.40) 150 1.14 (0.90, 1.45) 106 1.19 (0.91, 1.56) 28 1.11 (0.67, 1.84) 
BAFF 523/550 0.73 (0.64, 0.82) 104 0.98 (0.78, 1.23) 78 0.74 (0.56, 0.97) 150 0.46 (0.37, 0.57) 106 0.76 (0.62, 0.94) 28 0.88 (0.58, 1.34) 
sIL-2Rα 523/550 1.19 (1.02, 1.40) 104 1.09 (0.82, 1.44) 78 1.09 (0.77, 1.54) 150 1.59 (1.23, 2.06) 106 1.10 (0.83, 1.46) 28 1.95 (1.22, 3.10) 
CXCL13 523/550 1.18 (1.04, 1.34) 104 1.20 (0.96, 1.49) 78 1.22 (0.94, 1.59) 150 0.92 (0.74, 1.13) 106 1.45 (1.18, 1.78) 28 1.20 (0.80, 1.82) 
sCD30 523/550 1.26 (1.06, 1.48) 104 1.27 (0.96, 1.66) 78 1.80 (1.30, 2.50) 150 1.10 (0.84, 1.45) 106 1.13 (0.85, 1.52) 28 1.25 (0.76, 2.05) 
Abbreviations: NHL, non-Hodgkin lymphoma; B-NHL, B-cell NHL; SD, standard deviation; OR, odds ratio; CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; FL, follicular 
lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; and T-NHL, T-cell NHL; IL, interleukin; TNF, tumor necrosis factor; CRP, C-reactive protein; sCD14, soluble 
CD14; sGP130, soluble GP130; sTNF-R2, soluble tumor necrosis factor receptor-2; sIL-6Rα, soluble interleukin-6 receptor-α; BAFF, B-cell activating factor of the TNF family; sIL-2Rα, soluble 
interleukin-2 receptor-α; CXCL13, CXC chemokine ligand 13; sCD30, soluble CD30. 
* From multivariable logistic regression models that include all 13 immune markers in each model, adjusted for age at blood draw, time of day of blood draw, race and cohort. T-NHL models 
were not adjusted for race due to sparse cell counts. 
†
 Odds ratios and 95% confidence intervals were calculated per 1 standard deviation increase in biomarker concentration, based on batch effect-corrected log-transformed values with outliers 
removed, for Nurses’ Health Study and Health Professionals Follow-up Study cohorts combined. 
‡ Other B-NHL subtypes included Burkitt lymphoma (N=4), lymphoplasmacytic lymphoma (N=19), mantle cell lymphoma (N=20), marginal zone lymphoma (N=44), other B-NHL (N=20), and 
unclassified B-NHL (N=25). 
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Supplementary Methods 
 
Study Population 
The Nurses’ Health Study (NHS) was established in 1976 when 121 700 female nurses aged 30-
55 from 11 US states responded to a mailed questionnaire.1  The Health Professionals Follow-up 
Study (HPFS) was initiated in 1986 among 51 529 male US health professionals aged 40-75 at 
baseline. In 1989-90, 32 826 NHS participants contributed blood samples by methods described 
in detail elsewhere.2 Between 1993 and 1994, 18 018 men contributed blood samples via similar 
methods and protocols as for the NHS. Briefly, cohort members received phlebotomy kits, had 
blood drawn locally, then returned the samples via overnight courier. Upon arrival, samples were 
centrifuged, aliquotted and stored at -130°C.2  
Participants from both studies complete biennial questionnaires to update exposures and 
ascertain new disease diagnoses. Participant deaths are ascertained by next-of-kin, the postal 
service or routine searches of the National Death Index.3, 4 Cancer diagnoses identified by self-
report or via death follow-up are confirmed by medical record review with participant consent, 
or by linkage to tumor registries. Follow-up for NHS and HPFS participants submitting a blood 
sample has consistently been >99% in each cohort.   
Informed consent to participate in the cohorts was implied by return of study 
questionnaires; cohort members who contributed blood samples provided written informed 
consent at the time of specimen collection. The present study was conducted in accordance with 
the Declaration of Helsinki and approved by the Institutional Review Boards of the Brigham and 
Women’s Hospital and Harvard T.H. Chan School of Public Health.  
 
Case and Control Selection 
Among cohort members with archived blood samples we included all with confirmed incident 
non-Hodgkin lymphoma (NHL) diagnosed at least three months after date of blood draw and 
prior to December 31, 2010, with no history of other cancer (except non-melanoma skin cancer). 
NHL histologic subtype was classified as described previously5 and according to the World 
Health Organization classification for hematopoietic tumors by study pathologists (JCA, SJR).6, 7 
Subtypes were categorized for analysis according to guidelines from the International 
Lymphoma Epidemiology (InterLymph) Consortium.8, 9 Several major B-cell NHL subtypes 
were analyzed individually, including diffuse large B-cell lymphoma (DLBCL), follicular 
lymphoma (FL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). 
Other identified, less common subtypes of B-NHL were combined into an “other B-NHL” 
category. We categorized all T-cell NHLs (T-NHL) together and also defined a category of all B-
NHL cases. Confirmed cases that could not be further classified were omitted from subtype-
specific analyses.  
For each eligible NHL case, we matched one control with an archived blood sample and 
no history of cancer (other than non-melanoma skin cancer) as of the case’s diagnosis date. 
Matching factors included cohort/sex, age (±1 year), race/ethnicity (Caucasian, other), fasting 
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status at blood draw (≥8 hours or not), date of blood draw (±1 month), and time of day of blood 
draw (within 2-hour increments).  
 
Biomarker Assessment 
At most, samples had undergone two freeze-thaw cycles prior to immune marker testing. Assays 
were performed at the University of California, Los Angeles (LM, OMM), using multiplexed 
assay kits (Fluorokine MAP, R & D Systems, Minneapolis, MN) according to manufacturer 
directions, and a Bio-Plex 200 Luminex instrument and Bio-Plex analysis software (Bio-Rad, 
Hercules, CA).  Assay panel A (first panel from the Soluble Receptor Human Panel Multiplex 
Kit) included sCD30, sIL-2Rα (also known as sCD25), B-cell activating factor of the TNF 
family (BAFF, a B-cell stimulatory cytokine also known as B lymphocyte stimulator, BLyS) and 
CXCL13 (also known as B lymphocyte chemoattractant, BLC, or B cell-attracting chemokine 1, 
BCA-1). Panel B (also from the Soluble Receptor kit) comprised four soluble receptors [soluble 
CD14 (sCD14), soluble GP130 (sGP130), soluble IL-6 receptor (sIL-6Rα) and sTNF-R2] and C-
reactive protein (CRP).  Panel C (from the High Sensitivity Human Inflammation Multiplex Kit) 
included IL-6, IL-8, IL-10, and TNF-α. Specimens from matched cases and controls were 
handled in the same batches, with pairs of quality control (QC) specimens interspersed randomly 
in each batch (approximately 10% of samples) to monitor assay performance. Laboratory 
personnel were blinded to case/control status and the identity of QC specimens. 
 The overall coefficients of variation (CV) for the immune markers ranged from 3.9% 
(BAFF) to 14.3% (IL-6); for the three immune markers with overall CVs >10% (IL-6, IL-10, and 
TNF-α), within-batch CVs were all <8%. 
For each plate of samples tested for a given analyte, a biomarker- and plate-specific 
lower limit of detection (LLD) was defined. Observations below the LLD were assigned a value 
of one-half the plate-specific LLD for that marker. In addition, extrapolated values ≤0.1 pg/mL 
were considered unreliable and were similarly assigned a value of one-half the plate-specific 
LLD for that marker.10, 11 Biomarkers with recoded values include CRP (N=11), IL-10 (N=193), 
IL-6 (N=21), and IL-8 (N=5). All analyte concentrations were natural log-transformed to 
improve normality. 
Prior to testing study samples we performed pilot studies to ensure that the pre-
processing delays inherent in our blood collection protocols did not compromise biomarker 
reliability.2  For all but three analytes, intraclass correlation coefficients (ICC) calculated from 
samples with 0-, 24- and 48-hour delays indicated good to excellent reproducibility (all ICCs 
≥0.55, with most ≥0.80) across the time frame in which the study samples were returned for 
processing. However, for TNF-α, IL-8 and CXCL13, the reproducibility in samples processed 
>24 hours after blood draw was poor; thus, in analyses of those three markers we set values to 
missing for the samples with >24 hour processing delays (NHS: N= 35; HPFS: N=23). We10 and 
others12-14 have previously demonstrated acceptable to excellent within-person temporal stability 
over a period of up to two years for most biomarkers in the present analysis. Because measured 
concentrations of biomarkers were similar between cohorts (Supplementary Table 1), we 
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pooled data from the NHS and HPFS to maximize statistical power for subtype-specific and 
stratified analyses. 
 
Statistical Methods 
We implemented the batch calibration methods of Rosner et al. to diminish the potential 
influence of laboratory batch-related variability on biomarker-NHL associations.15 Briefly, for 
each analyte we calculated a “batch effect correction factor” using linear regression models run 
on natural log-transformed biomarker values and then utilized the batch-specific correction 
factors to normalize the measured laboratory values across batches.  
Outlying immune marker values were identified using the Rosner extreme Studentized 
deviate method.16 Records with implausible outlier values were omitted only from analyses of 
the given marker. We calculated partial Spearman correlation coefficients among the pooled 
controls with adjustment for age at blood draw and cohort to assess the pairwise correlations 
between the immune markers. 
The primary analysis assessed batch effect-corrected, log-transformed values of each 
immune marker continuously per standard deviation (SD) increase in concentration based on SD 
units calculated for the log-transformed variables in the pooled study controls. To permit 
inclusion of all the controls in subtype-specific analyses, we used unconditional logistic 
regression models to calculate odds ratios (OR) and 95% confidence intervals (CI) for the 
association between each immune marker and NHL risk, overall and by major histologic subtype 
(DLBCL, FL, CLL/SLL, other B-NHL, all B-NHL, all T-NHL). Most models adjusted for all the 
matching factors; we could not adjust for race in models for T-NHL and certain subgroup 
analyses due to small numbers. We evaluated additional potential confounding variables, 
including body mass index at blood draw (<22.5, 22.5-24.9, 25.0-29.9, ≥30 kg/m²) and in young 
adulthood (<18.5, 18.5-22.4, 22.5-24.9, ≥25 kg/m²) and self-reported history of autoimmune 
disease (rheumatoid arthritis, ulcerative colitis/Crohn disease, multiple sclerosis, psoriasis, and 
Sjögren syndrome). However, the addition of these variables to the multivariable model did not 
meaningfully change the reported associations, and thus only matching factors were retained in 
the final models. Exclusion of individuals with a history of autoimmune disease also did not 
influence the observed associations.  
Additional analyses explored associations between NHL risk and multiple immune 
markers. Our a priori approach to identifying multi-marker profiles consisted of mutual 
adjustment of markers that were individually associated with NHL risk (sTNF-R2, sIL-2Rα, 
CXCL13, sCD30, BAFF), with further adjustment for matching factors. We investigated these 5-
marker models for risk of all NHL and each major NHL subtype. For comparison we decided 
post hoc to explore multivariable, multi-marker models constructed using the automated stepwise 
regression procedure, with the matching factors forced in and the significance level set to 
p=0.10, as well as a multivariable model mutually adjusted for all 13 immune markers. 
We also examined models stratified by the time interval between blood draw and 
diagnosis (0 to <5, 5 to <10, and ≥10 years) to explore whether any immune biomarker 
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associations suggested only earlier or later influence on NHL pathogenesis. We assessed 
heterogeneity in associations by time period using the contrast test method.17 
Secondary analyses that we added post hoc included an examination of possible non-
linear relationships between NHL risk and immune markers, which we assessed non-
parametrically with restricted cubic splines,18 looking at risk of all NHL, B-NHL, T-NHL, and 
the four histologic subtypes of B-NHL (DLBCL, FL, CLL/SLL, other B-NHL). The 
unconditional logistic regression models included the five immune markers from the main multi-
marker models (sTNFR2, sIL2-Rα, CXCL13, sCD30, BAFF), and were additionally adjusted for 
age at blood draw, time of blood draw, cohort and race. 
In another post hoc exploratory analysis to compare with unconditional logistic 
regression, we utilized polytomous logistic regression (PLR) to better account for potential 
heterogeneity between strata, looking at all B-NHL and all T-NHL in one model, and the four 
histologic subtypes of B-NHL noted previously in a second model. Models examined the 
association between NHL and the same five immune markers (sTNF-R2, sIL-2Rα, CXCL13, 
sCD30, BAFF) as in the unconditional logistic regression multi-marker models for the total time 
period, and then stratified by time between blood draw and diagnosis/index date (0 to <5, 5 to 
<10, and ≥10 years). We created a semi-continuous variable with three levels, taking the value of 
the median of each time period, and constructed an interaction term between this variable and 
levels of each of the five main biomarkers (per-SD, natural log scale), which we included with 
the corresponding main effect terms to assess heterogeneity of the biomarker-endpoint 
associations across time periods. The PLR models were adjusted for age at blood draw 
(continuous), cohort, and time of blood draw (continuous). We could not adjust the PLR models 
for race due to small numbers in certain categories (T-NHL and earliest time period).  
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Supplementary Table 1. Description of immune markers by cohort (pg/mL) 
 
NHS 
 
HPFS 
Marker N Mean Median Minimum Maximum  N Mean Median Minimum Maximum 
Original values* 
IL-6 689 9.84 7.47 0.53 792.64 
 
510 8.51 7.19 1.19 57.24 
IL-8 654 30.23 8.76 1.54 6259.12 
 
487 11.14 5.85 0.63 1132.53 
IL-10 687 2.80 2.19 0.04 23.00 
 
507 2.85 2.21 0.20 13.05 
TNF-α 654 28.66 26.68 5.09 178.69 
 
487 29.74 28.45 7.36 65.86 
CRP† 689 11003967.73 4559642.35 209329.56 462764529.00 
 
510 8699651.28 2348826.14 11800.65 504457100.00 
sCD14 689 2142644.13 2025343.98 1080204.24 9922244.05 
 
510 1789479.58 1751751.90 1089323.23 3761290.34 
sGP130 689 370953.04 332034.91 223577.85 1986314.93 
 
510 316457.54 311519.56 161432.46 525071.11 
sTNF-R2 689 4290.46 3808.80 1722.62 22624.52 
 
510 4419.16 3869.31 1933.82 80532.09 
sIL-6Rα 689 80997.67 74227.80 26418.37 390419.22 
 
510 71172.14 68642.09 34127.68 157703.21 
BAFF 689 1432.82 1401.83 461.43 3159.70 
 
510 1234.76 1194.76 289.66 6083.44 
sIL-2Rα 689 1295.80 1136.68 492.48 8818.70 
 
510 1404.08 1191.71 376.05 12544.05 
CXCL13 654 57.85 37.81 7.57 3915.66 
 
487 102.73 37.19 6.41 21732.23 
sCD30 689 1532.96 1267.16 497.92 27976.35 
 
510 1435.95 1189.95 431.53 9573.50 
            Batch effect-corrected‡, LN-transformed values 
IL-6 687 1.98 1.98 0.02 4.10 
 
510 2.00 1.99 0.18 4.01 
IL-8 644 2.19 2.16 0.46 4.35 
 
480 1.77 1.76 0.05 3.55 
IL-10 686 0.75 0.78 -1.95 3.43 
 
507 0.82 0.83 -1.58 2.56 
TNF-α 650 3.26 3.27 2.13 4.37 
 
487 3.34 3.36 1.94 4.17 
CRP 689 15.31 15.29 12.41 19.82 
 
506 14.76 14.66 11.51 18.86 
sCD14 679 14.53 14.52 13.94 15.30 
 
509 14.39 14.38 13.90 14.88 
sGP130 689 12.76 12.72 12.33 14.41 
 
510 12.66 12.65 12.08 13.17 
sTNF-R2 688 8.29 8.26 7.46 9.55 
 
505 8.31 8.28 7.55 9.43 
sIL-6Rα 681 11.23 11.22 10.18 12.28 
 
510 11.16 11.15 10.49 11.97 
BAFF 686 7.25 7.25 6.36 8.07 
 
507 7.08 7.08 6.19 8.06 
sIL-2Rα 680 7.06 7.03 6.20 8.24 
 
505 7.12 7.08 5.93 8.47 
CXCL13 645 3.66 3.62 1.99 5.33 
 
480 3.67 3.61 1.85 5.62 
sCD30 684 7.19 7.14 6.31 8.76   506 7.15 7.09 6.03 8.59 
Abbreviations: NHS indicates Nurses' Health Study; HPFS, Health Professionals Follow-up Study; IL, interleukin; TNF, tumor necrosis factor; 
CRP, C-reactive protein; sCD14, soluble CD14; sGP130, soluble GP130; sTNF-R2, soluble tumor necrosis factor receptor-2; sIL-6Rα, soluble 
interleukin-6 receptor-α; BAFF, B-cell activating factor of the TNF family; sIL-2Rα, soluble interleukin-2 receptor-α; CXCL13, CXC chemokine 
ligand 13; sCD30, soluble CD30. 
* Original values including extrapolated values, but excluding observations with processing delays. 
  † CRP is presented in pg/mL for consistency; divide by 1X109 to convert to mg/dL. For example, 11003967.73 pg/mL = 0.01100396773 mg/dL. 
‡ Batch effect correction conducted per methods of Rosner, et al. (Am J Epidemiol 2008;167:653-66); batch-corrected Ns reflect exclusion of 
participants missing age at blood draw. 
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Supplementary Table 2. Pairwise Spearman correlation coefficients between immune markers among controls only, adjusted for 
age and cohort (sex)* 
 
IL-6 IL-8 IL-10 TNF-ɑ CRP sCD14 sGP130 sTNF-R2 sIL-6Rɑ BAFF sIL2-Rɑ CXCL13 sCD30 
IL-6 1.00 0.10 0.15 0.33 0.14 0.15 0.06 0.11 0.03 0.03 0.12 0.05 -0.01 
IL-8 
 
1.00 0.13 0.22 -0.03 0.13 0.05 0.10 0.002 0.05 0.15 0.17 0.10 
IL-10 
  
1.00 0.23 0.04 0.02 0.05 0.06 0.03 0.03 0.02 -0.03 0.04 
TNF-ɑ 
   
1.00 0.0001 0.14 0.13 0.13 0.01 0.04 0.04 0.06 0.14 
CRP 
    
1.00 0.22 0.04 0.25 0.09 0.07 0.19 0.07 -0.04 
sCD14 
     
1.00 0.38 0.42 0.21 0.18 0.24 0.11 0.12 
sGP130 
      
1.00 0.40 0.34 0.18 0.17 0.10 0.19 
sTNF-R2 
       
1.00 0.33 0.24 0.49 0.23 0.53 
sIL-6Rɑ 
        
1.00 0.03 0.12 0.06 0.10 
BAFF 
         
1.00 0.28 0.13 0.26 
sIL2-Rɑ 
          
1.00 0.26 0.58 
CXCL13 
           
1.00 0.32 
sCD30 
            
1.00 
Abbreviations: NHL, non-Hodgkin lymphoma; B-NHL, all B-cell NHL; T-NHL, all T-cell NHL; OR, odds ratio; CI, confidence interval; SD, standard 
deviation; IL, interleukin; TNF, tumor necrosis factor; CRP, C-reactive protein; sCD14, soluble CD14; sGP130, soluble GP130; sTNF-R2, soluble 
tumor necrosis factor receptor-2; sIL-6Rα, soluble interleukin-6 receptor-α; BAFF, B-cell activating factor of the TNF family; sIL-2Rα, soluble 
interleukin-2 receptor-α; CXCL13, CXC chemokine ligand 13; sCD30, soluble CD30. 
* Bold type signifies p < 0.0001. 
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Supplementary Table 3. Associations of individual pre-diagnosis plasma 
immune markers with NHL risk, overall and by major histologic subtype, 
separately for the Nurses’ Health Study (NHS) and the Health Professionals 
Follow-up Study (HPFS) participants 
 
Cohort 
 
NHS HPFS 
Marker 
N cases/ 
controls 
OR (95% CI)     
per 1-SD* 
N cases/ 
controls 
OR (95% CI)     
per 1-SD* 
All NHL 
IL-6 343/344 1.01 (0.87,1.17) 254/256 0.93 (0.79,1.09) 
IL-8 319/325 1.03 (0.88,1.20) 239/241 0.96 (0.81,1.15) 
IL-10 343/343 1.00 (0.87,1.16) 253/254 0.99 (0.83,1.17) 
TNF-α 323/327 1.01 (0.87,1.17) 243/244 1.03 (0.86,1.23) 
CRP 344/345 1.07 (0.92,1.25) 252/254 1.04 (0.87,1.23) 
sCD14 338/341 0.94 (0.81,1.09) 254/255 1.14 (0.96,1.35)       
sGP130 338/341 0.94 (0.78,1.14) 254/255 1.17 (0.98,1.40)       
sTNF-R2 343/345 1.20 (1.04,1.39) 249/256 1.34 (1.12,1.62) 
sIL-6Rα 338/343 1.08 (0.93,1.26)       254/256 1.11 (0.95,1.30) 
BAFF 341/345 0.88 (0.78,1.00)       251/256 0.79 (0.68,0.91) 
sIL-2Rα 335/345 1.31 (1.14,1.52) 250/255 1.45 (1.23,1.71) 
CXCL13 315/330 1.32 (1.15,1.51) 239/241 1.30 (1.10,1.54) 
sCD30 339/345 1.29 (1.12,1.49) 251/255 1.48 (1.26,1.74) 
     B-NHL Subtypes 
All B-NHL N cases 
 
N cases 
 IL-6 290 1.03 (0.89,1.21) 212 0.91 (0.77,1.07) 
IL-8 267 1.07 (0.91,1.26) 199 0.97 (0.81.1.16) 
IL-10 290 1.00 (0.86,1.16) 211 0.96 (0.80,1.14) 
TNF-α 271 0.99 (0.85,1.17) 202 0.98 (0.81,1.19) 
CRP 291 1.08 (0.92,1.27) 210 1.02 (0.85,1.23) 
sCD14 286 0.89 (0.76,1.05) 212 1.13 (0.94,1.35) 
sGP130 286 0.92 (0.75,1.12) 212 1.14 (0.95,1.37) 
sTNF-R2 290 1.20 (1.03,1.40) 207 1.36 (1.12,1.65) 
sIL-6Rα 286 1.07 (0.91,1.25) 212 1.10 (0.93,1.30) 
BAFF 288 0.86 (0.76,0.99) 209 0.75 (0.64,0.88) 
sIL-2Rα 285 1.31 (1.12,1.52) 208 1.48 (1.25,1.77) 
CXCL13 266 1.30 (1.12,1.50) 199 1.26 (1.06,1.50) 
sCD30 288 1.31 (1.12,1.52) 210 1.45 (1.22,1.72) 
     DLBCL 
    IL-6 70 1.14 (0.87,1.49) 44 1.08 (0.79,1.49) 
IL-8 63 0.97 (0.73,1.29) 43 0.97 (0.70,1.34) 
IL-10 69 1.08 (0.83,1.40) 44 1.26 (0.91,1.76) 
TNF-α 65 0.94 (0.72,1.24) 43 1.02 (0.73,1.42) 
CRP 70 1.00 (0.77,1.30) 44 1.34 (0.98,1.84) 
sCD14 70 0.80 (0.61,1.06) 44 1.15 (0.84,1.58) 
sGP130 70 0.78 (0.53,1.14) 44 1.03 (0.73,1.44) 
 11 
sTNF-R2 70 0.84 (0.63,1.12) 44 1.36 (0.98,1.89) 
sIL-6Rα 70 0.82 (0.62,1.09) 44 1.01 (0.74,1.40) 
BAFF 70 0.97 (0.76,1.24) 44 1.02 (0.75,1.38) 
sIL-2Rα 70 1.05 (0.80,1.37) 44 1.61 (1.19,2.19) 
CXCL13 65 1.21 (0.95,1.55) 42 1.31 (0.96,1.78) 
sCD30 70 1.14 (0.88,1.48) 44 1.51 (1.14,2.01) 
     FL 
    IL-6 63 1.04 (0.80,1.45) 29 0.63 (0.41,0.97) 
IL-8 58 1.16 (0.89,1.52) 26 0.84 (0.56,1.26) 
IL-10 63 1.03 (0.79,1.34) 28 0.90 (0.61,1.33) 
TNF-α 60 1.12 (0.84,1.48) 27 1.23 (0.80,1.88) 
CRP 63 1.23 (0.94,1.61) 29 0.87 (0.57,1.32) 
sCD14 61 0.82 (0.61,1.11) 29 1.30 (0.88,1.91) 
sGP130 62 1.11 (0.81,1.53) 29 1.34 (0.88,2.05) 
sTNF-R2 62 1.45 (1.11,1.90) 28 1.19 (0.78,1.84) 
sIL-6Rα 62 1.18 (0.90,1.55) 29 1.09 (0.74,1.60) 
BAFF 63 0.93 (0.72,1.21) 29 0.91 (0.61,1.36) 
sIL-2Rα 62 1.65 (1.26,2.17) 29 1.34 (0.92,1.96) 
CXCL13 59 1.66 (1.29,2.14) 27 1.46 (1.00,2.14) 
sCD30 62 1.86 (1.44,2.40) 28 1.51 (1.06,2.14) 
     CLL/SLL 
    IL-6 84 1.03 (0.80,1.31) 81 0.96 (0.76,1.21) 
IL-8 79 0.95 (0.74,1.23)† 77 1.03 (0.79,1.34) 
IL-10 84 0.83 (0.66,1.05) 81 0.87 (0.68,1.12) 
TNF-α 79 1.03 (0.80,1.32)† 79 1.10 (0.85,1.42) 
CRP 84 0.94 (0.73,1.20) 81 0.92 (0.71,1.19) 
sCD14 83 0.82 (0.63,1.06) 81 1.06 (0.82,1.35) 
sGP130 82 0.85 (0.60,1.20) 81 1.22 (0.95,1.56) 
sTNF-R2 84 1.16 (0.92,1.45) 80 1.49 (1.14,1.95) 
sIL-6Rα 84 1.19 (0.94,1.51) 81 1.11 (0.88,1.39) 
BAFF 84 0.58 (0.46,0.73) 79 0.48 (0.37,0.63) 
sIL-2Rα 82 1.40 (1.11,1.77) 80 1.61 (1.26,2.05) 
CXCL13 78 1.02 (0.80,1.30)† 78 1.19 (0.93,1.52) 
sCD30 83 1.19 (0.95,1.49) 80 1.56 (1.22,1.99) 
     Other B-NHL‡ 
    IL-6 73 0.96 (0.75, 1.23) 58 0.80 (0.60, 1.07) 
IL-8 67 1.23 (0.96, 1.57) 53 0.93 (0.69, 1.26) 
IL-10 74 1.15 (0.89, 1.48) 53 0.92 (0.70, 1.21) 
TNF-α 67 0.92 (0.71, 1.19) 58 0.72 (0.54, 0.96) 
CRP 74 1.23 (0.95, 1.59) 56 1.02 (0.75, 1.39) 
sCD14 72 1.13 (0.88, 1.44) 58 1.15 (0.86, 1.53) 
sGP130 72 0.94 (0.68, 1.29) 58 1.09 (0.81, 1.46) 
sTNF-R2 74 1.41 (1.12, 1.78) 55 1.25 (0.93, 1.68) 
 12 
sIL-6Rα 70 1.07 (0.83, 1.39) 58 1.21 (0.92, 1.60) 
BAFF 71 1.02 (0.80, 1.29) 57 0.77 (0.60, 0.99) 
sIL-2Rα 71 1.35 (1.05, 1.73) 55 1.48 (1.13, 1.95) 
CXCL13 64 1.61 (1.28, 2.03) 52 1.34 (1.02, 1.76) 
sCD30 73 1.24 (0.98, 1.59) 58 1.35 (1.06, 1.71) 
     All T-NHL§ 
IL-6 18 1.09 (0.68,1.74) 12 1.19 (0.65, 2.18) 
IL-8 18 0.61 (0.35, 1.08) 11 1.31 (0.66, 2.64) 
IL-10 18 1.00 (0.62, 1.61) 12 1.64 (0.87, 3.09) 
TNF-α 18 1.00 (0.61, 1.65) 11 1.37 (0.74, 2.54) 
CRP 18 0.87 (0.54, 1.41) 12 1.16 (0.63, 2.14) 
sCD14 18 0.78 (0.46, 1.34) 12 1.31 (0.65, 2.64) 
sGP130 18 0.70 (0.35, 1.37) 12 1.16 (0.42, 3.22) 
sTNF-R2 18 0.89 (0.54, 1.47) 12 1.30 (0.70, 2.41) 
sIL-6Rα 18 0.93 (0.59,1.46) 12 1.23 (0.61, 2.47) 
BAFF 18 1.15 (0.69, 1.92) 12 1.38 (0.83, 2.32) 
sIL-2Rα 18 1.79 (1.10, 2.92) 12 2.24 (1.28, 3.91) 
CXCL13 18 1.33 (0.83, 2.13) 10 1.12 (0.64, 1.97) 
sCD30 18 1.25 (0.81,1.92) 11 1.87 (1.12, 3.12) 
     Abbreviations:  NHL, non-Hodgkin lymphoma; NHS, Nurses’ Health Study; HPFS, Health 
Professionals Follow-up Study; B-NHL, all B-cell NHL; T-NHL, all T-cell NHL; OR, odds ratio; 
CI, confidence interval; SD, standard deviation; IL, interleukin; TNF, tumor necrosis factor; 
CRP, C-reactive protein; sCD14, soluble CD14; sGP130, soluble GP130; sTNF-R2, soluble 
tumor necrosis factor receptor-2; sIL-6Rα, soluble interleukin-6 receptor-α; BAFF, B-cell 
activating factor of the TNF family; sIL-2Rα, soluble interleukin-2 receptor-α; CXCL13, CXC 
chemokine ligand 13; sCD30, soluble CD30. 
* All models were adjusted for age at blood draw, time of day of blood draw and race unless 
otherwise noted. 
† Models were adjusted for age at blood draw and time of day of blood draw. 
‡ Other B-cell subtypes included Burkitt lymphoma (N=4), lymphoplasmacytic lymphoma 
(N=19), mantle cell lymphoma (N=20), marginal zone lymphoma (N=44), other B-NHL (N=20), 
and unclassified B-NHL (N=25). 
§ Models were adjusted for age at blood draw only. 
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Supplementary Table 4. Independent associations of multiple pre-diagnosis plasma immune markers with risk of NHL, overall and by B 
or T cell type of origin, for the complete follow-up period and stratified by years of follow-up, using polytomous logistic regression 
        Years from blood draw to diagnosis/index date   
  Complete follow-up period¶   0 to less than 5   5 to less than 10   10 or more   
Marker* 
N 
cases† 
OR (95% CI)  per 
1-SD ‡,^ 
  
N 
cases† 
OR (95% CI)  per 
1-SD ‡,^ 
  
N 
cases† 
OR (95% CI)  per 
1-SD ‡,^ 
  
N 
cases† 
OR (95% CI)  per 
1-SD ‡,^ 
P-
value§ 
All NHL‖                          
sTNF-R2 542 1.05 (0.91, 1.21)   133 0.83 (0.60, 1.14)   149 1.02 (0.77, 1.35)   260 1.18 (0.95, 1.46) 0.20 
sIL-2Rα 542 1.20 (1.03, 1.39)   133 1.52 (1.09, 2.11)   149 1.16 (0.88, 1.53)   260 1.11 (0.88, 1.39) 0.28 
CXCL13 542 1.17 (1.03, 1.32)   133 1.00 (0.78, 1.29)   149 1.30 (1.03, 1.62)   260 1.21 (1.01, 1.46) 0.32 
sCD30 542 1.24 (1.06, 1.45)   133 1.52 (1.09, 2.13)   149 1.43 (1.07, 1.90)   260 0.98 (0.78, 1.23) 0.02 
BAFF 542 0.74 (0.66, 0.83)   133 0.73 (0.59, 0.91)   149 0.61 (0.48, 0.78)   260 0.83 (0.69, 1.00) 0.15 
      
 
                  
All B-NHL                         
sTNF-R2 454 1.08 (0.93, 1.26)   110 0.91 (0.65, 1.25)   118 1.14 (0.85, 1.53)   226 1.14 (0.91, 1.44) 0.04 
sIL-2Rα 454 1.20 (1.03, 1.40)   110 1.46 (1.03, 2.07)   118 1.16 (0.87, 1.54)   226 1.14 (0.91, 1.44) 0.06 
CXCL13 454 1.14 (1.00, 1.29)   110 0.99 (0.75, 1.30)   118 1.19 (0.93, 1.51)   226 1.22 (1.02, 1.47) 0.46 
sCD30 454 1.24 (1.05, 1.46)   110 1.55 (1.09, 2.21)   118 1.57 (1.14, 2.16)   226 0.96 (0.75, 1.23) 0.03 
BAFF 454 0.74 (0.66, 0.83)   110 0.70 (0.56, 0.87)   118 0.64 (0.51, 0.81)   226 0.85 (0.71, 1.02) 0.30 
                          
All T-NHL                         
sTNF-R2 28 0.64 (0.39, 1.04)   11 0.54 (0.24, 1.22)   10 0.60 (0.26, 1.39)   7 0.74 (0.25, 2.21) 0.94 
sIL-2Rα 28 1.73 (1.11, 2.69)   11 2.10 (0.97, 4.53)   10 1.79 (0.90, 3.54)   7 0.96 (0.35, 2.62) 0.33 
CXCL13 28 1.03 (0.72, 1.47)   11 0.84 (0.46, 1.55)   10 1.48 (0.85, 2.58)   7 0.66 (0.32, 1.37) 0.64 
sCD30 28 1.30 (0.83, 2.03) 
 
11 1.47 (0.69, 3.14)   10 1.16 (0.53, 2.53)   7 1.90 (0.73, 4.93) 0.77 
BAFF 28 0.96 (0.70, 1.32)   11 1.00 (0.62, 1.60)   10 0.74 (0.43, 1.27)   7 1.32 (0.61, 2.86) 0.36 
Abbreviations: NHL, Non-Hodgkin lymphoma; B-NHL, all B-cell NHL; T-NHL, all T-cell NHL; OR, Odds Ratio; CI, Confidence Interval; SD, Standard Deviation; 
sTNF-R2, soluble tumor necrosis factor receptor-2; sIL-2Rα, soluble interleukin-2 receptor-α; CXCL13, CXC chemokine ligand 13; sCD30, soluble CD30; BAFF, 
B-cell activating factor of the TNF family. 
* Values are batch effect-corrected and exclude cohort-specific outliers. 
† The models for the full follow-up period included 571 controls. Each of the models for 0 to <5 year, 5 to <10 year and 10 or more year intervals after blood draw 
included 140, 162 and 267 controls, respectively. 
‡ Unstratified models adjusted for age at blood draw (continuous), cohort (HPFS, NHS), time of blood draw (continuous) and race/ethnicity (Caucasian, non-
Caucasian). The time-stratified models were not adjusted for race. The models were mutually adjusted for all immune markers listed. 
^ Odds Ratios and 95% Confidence Intervals were calculated per standard deviation of natural log-transformed values, in HPFS and NHS combined. 
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¶ In unstratified analyses, only sTNF-R2 demonstrated significant heterogeneity by tumor cell type (p=0.04); all other p-values for heterogeneity by tumor cell type 
were ≥0.10. 
§ P-values from tests for heterogeneity comparing effect estimates for each immune marker-endpoint association across time strata, based on inclusion of an 
interaction term for biomarker* time period in the corresponding model for the complete time period. 
‖ The all NHL models in italics are included for comparison purposes. These models used unconditional logistic regression, and were not compared statistically 
with any subtypes. 
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Supplementary Table 5. Independent associations of multiple pre-diagnosis plasma immune markers with risk of NHL by major histologic 
subtype of B-cell NHL for the complete follow-up period and stratified by years of follow-up, using polytomous logistic regression 
        Years from blood draw to diagnosis/index date   
  
Complete follow-up 
period* 
  0 to less than 5   5 to less than 10    10 or more 
  
Marker 
N 
cases† 
OR (95% CI)  
per 1-SD‡, § 
  
N 
cases† 
OR (95% CI)  
per 1-SD‡, §  
  
N 
cases† 
OR (95% CI)  
per 1-SD‡, §  
  
N 
cases† 
OR (95% CI)  
per 1-SD‡, §  
  P-
value¶ 
DLBCL                         
sTNF-R2 107 0.83 (0.64, 1.08)   25 0.65 (0.37, 1.15)   25 0.99 (0.58, 1.69)   57 0.85 (0.56, 1.28)   0.20 
sIL-2Rα 107 1.13 (0.87, 1.45)   25 1.65 (0.91, 2.99)   25 1.01 (0.61, 1.65)   57 1.07 (0.73, 1.57)   0.20 
CXCL13 107 1.14 (0.93, 1.40)   25 0.76 (0.47, 1.21)   25 1.40 (0.95, 2.07)   57 1.27 (0.95, 1.71)   0.21 
sCD30 107 1.24 (0.96, 1.62)   25 0.99 (0.53, 1.83)   25 1.93 (1.18, 3.18)   57 1.10 (0.75, 1.62)   0.98 
BAFF 107 0.94 (0.78, 1.14)   25 0.98 (0.66, 1.46)   25 0.68 (0.47, 0.97)   57 1.11 (0.83, 1.48)   0.47 
                            
FL                           
sTNF-R2 83 1.04 (0.78, 1.38)   18 0.65 (0.30, 1.42)   22 0.91 (0.52, 1.59)   43 1.45 (0.99, 2.10)   0.0007 
sIL-2Rα 83 1.01 (0.76, 1.34)   18 0.74 (0.35, 1.56)   22 1.12 (0.67, 1.87)   43 1.03 (0.68, 1.55)   0.95 
CXCL13 83 1.21 (0.97, 1.51)   18 0.86 (0.53, 1.41)   22 1.14 (0.74, 1.75)   43 1.42 (1.03, 1.97)   0.15 
sCD30 83 1.65 (1.24, 2.19)   18 4.34 (2.13, 8.85)   22 1.67 (0.96, 2.90)   43 1.08 (0.70, 1.67)   0.001 
BAFF 83 0.81 (0.66, 0.99)   18 0.79 (0.50, 1.24)   22 0.83 (0.55, 1.23)   43 0.78 (0.57, 1.06)   0.40 
                            
CLL/SLL                         
sTNF-R2 153 1.23 (0.99, 1.53)   36 1.03 (0.61, 1.71)   44 1.33 (0.88, 2.02)   73 1.20 (0.86, 1.66)   0.29 
sIL-2Rα 153 1.40 (1.12, 1.74)   36 2.43 (1.40, 4.23)   44 1.34 (0.90, 2.00)   73 1.19 (0.85, 1.67)   0.008 
CXCL13 153 0.88 (0.73, 1.06)   36 0.79 (0.50, 1.22)   44 0.75 (0.51, 1.11)   73 1.00 (0.76, 1.30)   0.30 
sCD30 153 1.20 (0.94, 1.52)   36 1.42 (0.82, 2.47)   44 1.59 (1.01, 2.53)   73 0.93 (0.65, 1.34)   0.18 
BAFF 153 0.55 (0.46, 0.65)   36 0.46 (0.33, 0.65)   44 0.48 (0.34, 0.67)   73 0.70 (0.54, 0.91)   0.10 
                            
Other B-NHL‖                         
sTNF-R2 111 1.17 (0.92, 1.49)   31 1.16 (0.72, 1.86)   27 1.19 (0.73, 1.94)   53 1.13 (0.78, 1.66)   0.69 
sIL-2Rα 111 1.16 (0.91, 1.48)   31 1.19 (0.71, 2.00)   27 1.03 (0.64, 1.64)   53 1.28 (0.87, 1.87)   0.74 
CXCL13 111 1.45 (1.19, 1.75)   31 1.41 (0.95, 2.09)   27 1.66 (1.16, 2.37)   53 1.32 (0.97, 1.80)   0.46 
 16 
 
sCD30 111 1.05 (0.81, 1.37)   31 1.47 (0.86, 2.50)   27 1.26 (0.76, 2.10)   53 0.80 (0.52, 1.21)   0.13 
BAFF 111 0.81 (0.68, 0.97) 
 
31 0.72 (0.52, 1.00)   27 0.74 (0.53, 1.06)   53 0.92 (0.69, 1.23)   0.56 
Abbreviations: NHL, Non-Hodgkin lymphoma; B-NHL, all B-cell NHL; T-NHL, all T-cell NHL; OR, Odds Ratio; CI, Confidence Interval; SD, Standard 
Deviation; sTNF-R2, soluble tumor necrosis factor receptor-2; sIL-2Rα, soluble interleukin-2 receptor-α; CXCL13, CXC chemokine ligand 13; sCD30, 
soluble CD30; BAFF, B-cell activating factor of the TNF family. 
* In unstratified analyses, CXCL13 (p=0.0007) and BAFF (p<0.0001) demonstrated significant heterogeneity by B-NHL histologic subtype; all other p-
values for heterogeneity by B-NHL histologic subtype were ≥0.08. 
† Each model for the complete follow-up period included 571 controls.  Each model for the 0 to <5, 5 to <10 and 10 or more year intervals after blood 
draw included 140, 162 and 267 controls, respectively. 
‡ Unstratified models adjusted for age at blood draw (continuous), cohort (sex), time of blood draw (continuous) and race/ethnicity (Caucasian, non-
Caucasian); time-stratified models were not adjusted for race. Models were mutually adjusted for all immune markers listed.  
§ Odds ratios and 95% confidence intervals were calculated per standard deviation of batch effect-corrected, log-transformed values from the 
combined Nurses’ Health Study and Health Professionals Follow-up Study cohorts. 
¶ P-values from test for heterogeneity comparing immune marker-specific effect estimates across time strata, based on inclusion of interaction terms 
for biomarker*time period in the PLR model for the complete follow-up period. 
‖ Other B-NHL subtypes include Burkitt lymphoma (N=4), lymphoplasmacytic lymphoma (N=19), mantle cell lymphoma (N=20), marginal zone 
lymphoma (N=39), other B-NHL (N=20), and unclassified B-NHL (N=25).  
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Supplementary Table 6. Associations of pre-diagnosis plasma immune marker profiles created through stepwise selection with risk of 
NHL, overall and by major histologic subtype of NHL, for the complete follow-up period and stratified by years from blood draw to 
diagnosis/index date 
      Years from blood draw to diagnosis/index date 
 
Complete Follow-up Period 0 to less than 5 5 to less than 10 10 or more 
Marker* 
N cases/ 
controls 
OR per 1-SD           
(95% CI)†,‡ 
N cases/ 
controls 
OR per 1-SD           
(95% CI)†,‡ 
N cases/ 
controls 
OR per 1-SD           
(95% CI)†,‡ 
N cases/ 
controls 
OR per 1-SD (95% 
CI)†,‡ 
All NHL                 
   sCD30 544/571 1.26 (1.08, 1.46) 134/140 1.48 (1.06, 2.05) 149/162 1.59 (1.19, 2.12) 261/267 1.03 (0.83, 1.28) 
   BAFF 544/571 0.74 (0.66, 0.83) 134/140 0.72 (0.58, 0.90) 149/162 0.61 (0.48, 0.78) 261/267 0.85 (0.70, 1.02) 
   CXCL13 544/571 1.17 (1.04, 1.32) 134/140 1.00 (0.78, 1.28) 149/162 1.30 (1.03, 1.63) 261/267 1.22 (1.01, 1.46) 
   sIL-2Rɑ 544/571 1.21 (1.05, 1.40) 134/140 1.41 (1.05, 1.89) 149/162 1.16 (0.89, 1.53) 261/267 1.15 (0.92, 1.43) 
         
B-NHL Subtypes        
DLBCL 
        
   sCD30 114/599 1.29 (1.06, 1.56) 26/154 0.96 (0.62, 1.49) 27/165 1.92 (1.30, 2.84) 61/278 1.18 (0.90, 1.54) 
         
FL§ 
        
   sCD30 90/598 1.76 (1.43, 2.15) 21/154 3.10 (1.93, 4.98) 22/164 1.75 (1.15, 2.67) 47/278 1.32 (0.98, 1.76) 
         
CLL/SLL§ 
        
   sCD30 160/594 1.20 (0.96, 1.51) 37/153 1.46 (0.78, 2.74) 46/163 1.59 (1.06, 2.40) 77/276 0.98 (0.70, 1.36) 
   BAFF 160/594 0.48 (0.39, 0.59) 37/153 0.32 (0.20, 0.53) 46/163 0.40 (0.26, 0.61) 77/276 0.67 (0.49, 0.92) 
   IL-10 160/594 0.83 (0.69, 0.99) 37/153 0.99 (0.63, 1.56) 46/163 0.78 (0.53, 1.13) 77/276 0.77 (0.60, 0.99) 
   sIL-2Rɑ 160/594 1.52 (1.22, 1.90) 37/153 3.07 (1.68, 5.62) 46/163 1.36 (0.89, 2.08) 77/276 1.21 (0.85, 1.71) 
         
Other B-NHL‖ 
 
    
  
   CXCL13 111/569 1.48 (1.22, 1.79) 31/140 1.64 (1.13, 2.38) 27/160 1.56 (1.11, 2.19) 53/267 1.30 (0.95, 1.76) 
   BAFF 111/569 0.80 (0.67, 0.97) 31/140 0.80 (0.59, 1.09) 27/160 0.78 (0.53, 1.15) 53/267 0.87 (0.62, 1.20) 
   sIL-2Rɑ 111/569 1.25 (1.02, 1.53) 31/140 1.41 (0.97, 2.05) 27/160 1.27 (0.82, 1.95) 53/267 1.19 (0.86, 1.65) 
         
T-cell NHL§             
   sIL-2Rɑ 30/598 1.97 (1.37, 2.85) 13/154 2.26 (1.31, 3.89) 10/164 1.91 (0.93, 3.92) 7/278 1.30 (0.59, 2.85) 
Abbreviations: NHL, non-Hodgkin lymphoma; OR, odds ratio; CI, confidence interval; SD, standard deviation; DLBCL, diffuse large B-cell lymphoma; FL, 
follicular lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; IL, interleukin; sTNF-R2, soluble tumor necrosis factor receptor-2; 
sIL-2Rα, soluble interleukin-2 receptor-α; CXCL13, CXC chemokine ligand 13; sCD30, soluble CD30; BAFF, B-cell activating factor of the TNF family. 
* Immune markers are listed in the order in which they were selected through the stepwise selection procedure. 
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† Odds ratios and 95% confidence intervals were calculated per 1 standard deviation increase in biomarker concentration, based on batch effect-corrected, 
log-transformed values with outliers removed, for Nurses’ Health Study and Health Professionals Follow-up Study cohorts combined. 
‡ All models were adjusted for age at blood draw, race, time of blood draw, cohort, and the other listed biomarkers unless otherwise noted. 
§ T-NHL models were not adjusted for race due to sparse cell counts. 
‖ Other B-cell subtypes included Burkitt lymphoma (N=4), lymphoplasmacytic lymphoma (N=19), mantle cell lymphoma (N=20), marginal zone lymphoma 
(N=44), other B-NHL (N=20), and unclassified B-NHL (N=25); time-stratified models for other B-NHL not adjusted for race due to sparse cell counts. 
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Supplementary Table 7. Associations of individual pre-diagnosis plasma immune markers with risk of all NHL, 
stratified by years of follow-up 
 Years from blood draw to diagnosis/index date  
 0 to less than 5  5 to less than 10  10 or more  
Marker 
N cases/ 
controls 
OR (95% CI) 
per 1-SD*,† 
 
N cases/ 
controls 
OR (95% CI) 
per 1-SD* 
 
N cases/ 
controls 
OR (95% CI) 
per 1-SD* 
 
IL-6 154/155 1.01 (0.81, 1.24)  165/165 0.87 (0.71, 1.07)  278/278 1.03 (0.88, 1.22)  
IL-8 142/141 1.04 (0.81, 1.33)  154/158 1.09 (0.85, 1.39)  262/265 0.92 (0.77, 1.11)  
IL-10 154/154 1.08 (0.87, 1.34)  165/165 0.98 (0.80, 1.21)  277/276 0.96 (0.82, 1.13)  
TNF-α 145/142 1.09 (0.87, 1.36)  156/159 0.92 (0.73, 1.17)  265/268 1.03 (0.87, 1.22)  
CRP 154/154 1.09 (0.88, 1.35)  164/165 1.08 (0.86, 1.37)  278/278 1.03 (0.87, 1.24)  
sCD14 153/154 1.07 (0.84, 1.37)  166/165 1.07 (0.86, 1.33)  273/275 0.94 (0.78, 1.14)  
sGP130 154/155 0.89 (0.66, 1.20)  165/164 1.28 (0.96, 1.72)  273/275 0.98 (0.80, 1.19)  
sTNF-R2 149/155 1.29 (1.03, 1.61)  166/166 1.27 (1.02, 1.59)  277/278 1.22 (1.03, 1.45) ‡ 
sIL-6Rα 153/155 0.97 (0.77, 1.21)  164/165 1.20 (0.97, 1.49)  275/277 1.11 (0.94, 1.31)  
BAFF 152/155 0.79 (0.67, 0.94)  163/166 0.73 (0.59, 0.89)  277/278 0.95 (0.80, 1.12) ‡ 
sIL-2Rα 147/154 1.80 (1.45, 2.23)  163/166 1.40 (1.14, 1.73)  275/278 1.14 (0.96, 1.35) ‡ 
CXCL13 139/140 1.34 (1.10, 1.64)  152/162 1.38 (1.13, 1.69)  263/267 1.25 (1.05, 1.48) ‡ 
sCD30 150/154 1.60 (1.30, 1.98)  164/166 1.61 (1.29, 2.00)  276/278 1.13 (0.96, 1.33) ‡ 
Abbreviations: NHL, non-Hodgkin lymphoma; OR, odds ratio; CI, confidence interval; SD, standard deviation; IL, interleukin; 
TNF, tumor necrosis factor; CRP, C-reactive protein; sCD14, soluble CD14; sGP130, soluble GP130; sTNF-R2, soluble 
tumor necrosis factor receptor-2; sIL-6Rα, soluble interleukin-6 receptor-α; BAFF, B-cell activating factor of the TNF family; 
sIL-2Rα, soluble interleukin-2 receptor-α; CXCL13, CXC chemokine ligand 13; sCD30, soluble CD30. 
* Adjusted for age at blood draw, time of day of blood draw, race, and cohort (sex). 
† Odds Ratios (OR) per 1 standard deviation increase in biomarker concentration, based on batch effect-corrected values 
with outliers removed, for Nurses’ Health Study and Health Professionals Follow-up Study cohorts combined. 
‡ Statistically significant in non-stratified models (Table 2). 
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Supplementary Table 8. Associations of individual plasma immune markers and risk of major histologic 
subtypes of NHL in the combined cohorts, stratified by years of follow-up 
 Years from blood draw to diagnosis/index date 
 
0 to less than 5 5 to less than 10 10 or more 
Marker 
N cases/ 
controls 
OR (95% CI)  
per 1-SD*,† 
N cases/ 
controls 
OR (95% CI)  
per 1-SD*,† 
N cases/ 
controls 
OR (95% CI)  
per 1-SD*,† 
B-NHL subtypes 
DLBCL 
IL-6 26/155 1.12 (0.71, 1.78) 27/164 1.01 (0.67, 1.54) 61/278 1.17 (0.88, 1.55) 
IL-8 26/141 0.87 (0.54, 1.40) 24/157 1.22 (0.77, 1.93) 56/265 0.89 (0.64, 1.25) 
IL-10 26/154 1.05 (0.69, 1.61) 27/164 1.11 (0.75, 1.65) 60/276 1.22 (0.91, 1.65) 
TNF-α 26/142 1.07 (0.69, 1.66) 25/158 0.97 (0.62, 1.51) 57/268 0.98 (0.73, 1.31) 
CRP 26/154 1.18 (0.79, 1.78) 27/164 1.32 (0.85, 2.06) 61/278 1.03 (0.77, 1.38) 
sCD14 26/154 1.10 (0.70, 1.73) 27/164 1.00 (0.65, 1.53) 61/275 0.80 (0.57, 1.12) 
sGP130 26/155 0.47 (0.22, 1.01) 27/163 1.03 (0.60, 1.77) 61/275 0.90 (0.62, 1.30) 
sTNF-R2 26/155 0.80 (0.51, 1.24) 27/165 1.37 (0.88, 2.14) 61/278 1.04 (0.77, 1.40) 
sIL-6Rα 26/155 0.74 (0.45, 1.21) 27/164 1.05 (0.70, 1.58) 61/277 0.87 (0.64, 1.19) 
BAFF 26/155 0.86 (0.57, 1.28) 27/165 0.78 (0.51, 1.20) 61/278 1.20 (0.89, 1.61) 
sIL-2Rα 26/154 1.33 (0.92, 1.91) 27/165 1.74 (1.10, 2.76) 61/278 1.12 (0.85, 1.49) 
CXCL13 25/140 0.74 (0.46, 1.18) 25/161 1.63 (1.14, 2.31) 57/267 1.35 (1.01, 1.81) 
sCD30 26/154 0.96 (0.62, 1.49) 27/165 1.92 (1.30, 2.84) 61/278 1.18 (0.90, 1.54) 
FL 
IL-6 22/155 0.71 (0.44, 1.15) 22/163 0.91 (0.58, 1.41) 48/278 0.99 (0.74, 1.33) 
IL-8 20/141 1.23 (0.76, 2.01) 21/156 1.07 (0.66, 1.73) 43/265 1.01 (0.72, 1.41) 
IL-10 22/154 0.68 (0.43, 1.06) 21/163 1.02 (0.65, 1.61) 48/276 1.14 (0.83, 1.57) 
TNF-α 20/142 1.19 (0.71, 1.97) 22/157 1.32 (0.79, 2.19) 45/268 1.10 (0.80, 1.51) 
CRP 22/154 1.02 (0.65, 1.60) 22/163 0.96 (0.58, 1.58) 48/278 1.25 (0.91, 1.73) 
sCD14 22/154 1.15 (0.71, 1.85) 22/163 0.59 (0.34, 1.02) 46/275 1.15 (0.79, 1.65) 
sGP130 22/155 0.64 (0.31, 1.33) 22/162 1.23 (0.73, 2.10) 47/275 1.29 (0.96, 1.74) 
sTNF-R2 21/155 1.34 (0.83, 2.17) 22/164 1.25 (0.78, 2.00) 47/278 1.45 (1.08, 1.94) 
sIL-6Rα 22/155 1.17 (0.73, 1.88) 22/163 1.06 (0.69, 1.63) 47/277 1.21 (0.90, 1.62) 
BAFF 22/155 0.86 (0.56, 1.33) 22/164 0.96 (0.58, 1.59) 48/278 0.92 (0.66, 1.29) 
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sIL-2Rα 22/154 2.29 (1.46, 3.60) 22/164 1.40 (0.90, 2.19) 47/278 1.30 (0.94, 1.79) 
CXCL13 20/140 2.22 (1.41, 3.50) 22/160 1.22 (0.82, 1.81) 44/267 1.65 (1.19, 2.29) 
sCD30 21/154 3.10 (1.93, 4.98) 22/164 1.75 (1.15, 2.67) 47/278 1.32 (0.98, 1.76) 
CLL/SLL 
IL-6 41/155 1.20 (0.86, 1.66) 47/163 0.89 (0.64, 1.23) 77/278 0.98 (0.76, 1.27) 
IL-8 38/141 1.37 (0.91, 2.06) 45/156 1.17 (0.80, 1.70) 73/265 0.75 (0.56, 1.01) 
IL-10 41/154 1.07 (0.75, 1.51) 47/163 0.87 (0.63, 1.19) 77/276 0.75 (0.58, 0.96) 
TNF-α 40/142 1.17 (0.83, 1.65) 45/157 0.96 (0.67, 1.37) 73/268 1.04 (0.80, 1.35) 
CRP 41/154 1.05 (0.76, 1.45) 47/163 0.85 (0.59, 1.24) 77/278 0.89 (0.67, 1.18) 
sCD14 41/154 1.03 (0.71, 1.52) 47/163 1.18 (0.84, 1.66) 76/275 0.69 (0.50, 0.94) 
sGP130 41/155 0.91 (0.55, 1.51) 47/162 1.57 (1.05, 2.36) 75/275 0.78 (0.54, 1.12) 
sTNF-R2 40/155 1.66 (1.16, 2.38) 47/164 1.44 (1.04, 2.00) 77/278 1.06 (0.82, 1.36) 
sIL-6Rα 41/155 0.97 (0.68, 1.40) 47/163 1.38 (1.01, 1.89) 77/277 1.11 (0.87, 1.42) 
BAFF 39/155 0.36 (0.24, 0.53) 47/164 0.47 (0.32, 0.68) 77/278 0.70 (0.52, 0.93) 
sIL-2Rα 39/154 2.79 (1.90, 4.09) 46/164 1.50 (1.09, 2.07) 77/278 1.05 (0.80, 1.38) 
CXCL13 38/140 1.35 (1.00, 1.81) 45/160 0.99 (0.72, 1.37) 73/267 1.02 (0.78, 1.34) 
sCD30 40/154 2.36 (1.59, 3.51) 46/164 1.51 (1.11, 2.04) 77/278 0.96 (0.74, 1.24) 
Other B-NHL‡ 
IL-6 38/155 1.00 (0.69, 1.45) 37/163 0.76 (0.55, 1.06) 56/278 0.95 (0.71, 1.27) 
IL-8 33/141 1.01 (0.68, 1.51) 33/156 1.13 (0.76, 1.68) 54/265 1.15 (0.85, 1.56) 
IL-10 38/154 1.22 (0.87, 1.71) 38/163 1.05 (0.75, 1.47) 56/276 0.89 (0.66, 1.20) 
TNF-α 33/142 0.98 (0.68, 1.39) 33/157 0.62 (0.42, 0.92) 54/268 0.86 (0.64, 1.16) 
CRP 38/154 1.22 (0.86, 1.74) 36/163 1.14 (0.76, 1.71) 56/278 1.15 (0.85, 1.57) 
sCD14 37/154 1.13 (0.77, 1.68) 38/163 1.30 (0.93, 1.81) 55/275 1.00 (0.70, 1.41) 
sGP130 38/155 1.18 (0.76, 1.81) 37/162 1.10 (0.71, 1.71) 55/275 0.87 (0.60, 1.28) 
sTNF-R2 35/155 1.54 (1.09, 2.17) 38/164 1.42 (1.01, 1.99) 56/278 1.20 (0.90, 1.59) 
sIL-6Rα 37/155 1.11 (0.76, 1.64) 36/163 1.07 (0.75, 1.52) 55/277 1.18 (0.89, 1.56) 
BAFF 38/155 0.85 (0.64, 1.12) 35/164 0.89 (0.65, 1.24) 55/278 0.95 (0.69, 1.29) 
sIL-2Rα 34/154 1.71 (1.23, 2.38) 36/164 1.47 (1.01, 2.12) 56/278 1.19 (0.89, 1.60) 
CXCL13 33/140 1.75 (1.25, 2.44) 29/160 1.41 (1.03, 1.94) 54/267 1.31 (0.98, 1.76) 
sCD30 38/154 1.40 (1.05, 1.87) 37/164 1.55 (1.10, 2.19) 56/278 1.05 (0.79, 1.40) 
All T-NHL 
 22 
IL-6 13/155 0.98 (0.53, 1.79) 10/163 1.30 (0.67, 2.53) 7/278 1.13 (0.53, 2.39) 
IL-8 12/141 0.70 (0.36, 1.35) 10/156 1.18 (0.59, 2.36) 7/265 0.66 (0.27, 1.65) 
IL-10 13/154 1.30 (0.73, 2.33) 10/163 0.76 (0.42, 1.39) 7/276 2.21 (0.90, 5.45) 
TNF-α 12/142 0.93 (0.52, 1.64) 10/157 1.18 (0.58, 2.41) 7/268 1.56 (0.70, 3.46) 
CRP 13/154 0.83 (0.48, 1.45) 10/163 2.05 (0.99, 4.28) 7/278 0.54 (0.22, 1.29) 
sCD14 13/154 1.01 (0.54, 1.89) 10/163 0.86 (0.43, 1.73) 7/275 0.93 (0.38, 2.29) 
sGP130 13/155 0.98 (0.46, 2.09) 10/162 0.86 (0.33, 2.23) 7/275 0.59 (0.19, 1.84) 
sTNF-R2 13/155 1.13 (0.63, 2.01) 10/164 0.85 (0.41, 1.76) 7/278 1.01 (0.47, 2.17) 
sIL-6Rα 13/155 0.72 (0.37, 1.37) 10/163 1.17 (0.65, 2.13) 7/277 1.26 (0.65, 2.43) 
BAFF 13/155 1.38 (0.86, 2.22) 10/164 0.74 (0.34, 1.60) 7/278 1.63 (0.70, 3.81) 
sIL-2Rα 13/154 2.26 (1.31, 3.89) 10/164 1.91 (0.93, 3.92) 7/278 1.30 (0.59, 2.85) 
CXCL13 11/140 1.23 (0.66, 2.29) 10/160 1.40 (0.85, 2.30) 7/267 0.72 (0.30, 1.70) 
sCD30 12/154 1.74 (1.01, 2.97) 10/164 1.33 (0.72, 2.45) 7/278 1.49 (0.75, 2.95) 
Abbreviations: NHL, non-Hodgkin lymphoma; OR, odds ratio; CI, confidence interval; SD, standard deviation; B-NHL, B-cell NHL; 
DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic 
lymphoma; and T-NHL, T-cell NHL; IL, interleukin; TNF, tumor necrosis factor; CRP, C-reactive protein; sCD14, soluble CD14; 
sGP130, soluble GP130; sTNF-R2, soluble tumor necrosis factor receptor-2; sIL-6Rα, soluble interleukin-6 receptor-α; BAFF, B-cell 
activating factor of the TNF family; sIL-2Rα, soluble interleukin-2 receptor-α; CXCL13, CXC chemokine ligand 13; sCD30, soluble 
CD30. 
* Adjusted for age at blood draw, time of day of blood draw, and cohort (sex). 
† Odds Ratios (OR) per 1 standard deviation increase in biomarker concentration, based on batch effect-corrected values with 
outliers removed, for Nurses’ Health Study and Health Professionals Follow-up Study cohorts combined. 
‡ Other B-cell subtypes include Burkitt lymphoma (N=4), lymphoplasmacytic lymphoma (N=19), mantle cell lymphoma (N=20), 
marginal zone lymphoma (N=44), other B-NHL (N=20), and unclassified B-NHL (N=25). 
 
